

 



<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
  "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"
      xmlns:foaf="http://xmlns.com/foaf/0.1/"
      xmlns:dc="http://purl.org/dc/terms/"
      xmlns:doi="http://dx.doi.org/"
      xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
      xmlns:xsd="http://www.w3.org/2001/XMLSchema-datatypes#"
      lang="en" xml:lang="en"
      itemscope itemtype="http://schema.org/Article"
      class="no-js">
<head prefix="og: http://ogp.me/ns#">
  <title>PLOS ONE: HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients</title>


<link rel="stylesheet" type="text/css"  href="/css/global-min.css?v=izteQ6tu7kgsJZW_xmrYizvKiHM" />


    <!--[if lte IE 7]>
<link rel="stylesheet" type="text/css"  href="/css/lte_ie7-min.css?v=3bykQUyQmReeuobVyPozcJ9LxRc" />
    <![endif]-->


<link rel="stylesheet" type="text/css"  href="/css/jquery-ui-min.css?v=eXDHTEJM0lIAmDe5k0I0Ad4nxNo" />


<link rel="stylesheet" type="text/css"  href="/css/journal.css?v=T7ZVxJfgk9jNxLAJ2qHz1vZpgYU" />


<link rel="stylesheet" type="text/css" media="print" href="/css/print-min.css?v=T5lb0B3q6EXBsuDluc5V5w+AkRc" />


  <link rel="stylesheet" href="http://f.fontdeck.com/s/css/js/www.plosone.org/24557.css" type="text/css"/>

  <!--chartbeat -->
  <script type="text/javascript">var _sf_startpt = (new Date()).getTime()</script>
  <script>document.documentElement.className += ' js';</script>

  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <meta http-equiv="X-UA-Compatible" content="IE=EmulateIE7; IE=EmulateIE9"/>
  <meta name="description" content="PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world."/>
  <meta name="keywords" content="PLOS, Public Library of Science, Open Access, Open-Access, Science, Medicine, Biology, Research, Peer-review, Inclusive, Interdisciplinary, Ante-disciplinary, Physics, Chemistry, Engineering"/>
  <meta name="almHost" content="http://alm.plos.org/api/v3/articles"/>
  <meta name="searchHost" content="http://api.plos.org/search" />
  <meta name="termsHost" content="http://api.plos.org/terms" />
  <meta name="solrApiKey" content="plos"/>
  <meta name="almAPIKey" content="3pezRBRXdyzYW6ztfwft" />
  <meta name="currentJournal" content="PLoSONE" />
  <meta name="almRequestBatchSize" content="" />

  <meta name="citation_publisher" content="Public Library of Science"/>
  <meta name="citation_doi" content="10.1371/journal.pone.0001138"/>
  <meta name="dc.identifier" content="10.1371/journal.pone.0001138" />

    <meta name="citation_title" content="HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients"/>
    <meta itemprop="name" content="HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients"/>

      <meta name="citation_author" content="Marianne Tuefferd"/>
            <meta name="citation_author_institution" content="JE2492, Université Paris-Sud, IFR69, Villejuif, France"/>
      <meta name="citation_author" content="Jérôme Couturier"/>
            <meta name="citation_author_institution" content="Service de Génétique Oncologique, Institut Curie, Paris, France"/>
      <meta name="citation_author" content="Frédérique Penault-Llorca"/>
            <meta name="citation_author_institution" content="Departement de Pathologie, Centre Jean Perrin, Clermont-Ferrand, France"/>
      <meta name="citation_author" content="Anne Vincent-Salomon"/>
            <meta name="citation_author_institution" content="Service de Pathologie, Institut Curie, Paris, France"/>
      <meta name="citation_author" content="Philippe Broët"/>
            <meta name="citation_author_institution" content="JE2492, Université Paris-Sud, IFR69, Villejuif, France"/>
      <meta name="citation_author" content="Jean-Paul Guastalla"/>
            <meta name="citation_author_institution" content="Centre Léon Bérard, Lyon, France"/>
      <meta name="citation_author" content="Djelila Allouache"/>
            <meta name="citation_author_institution" content="Centre François Baclesse, Caen, France"/>
      <meta name="citation_author" content="Martin Combe"/>
            <meta name="citation_author_institution" content="Service de Médecine Interne-Oncologie, Centre Hospitalier, Le Mans, France"/>
      <meta name="citation_author" content="Béatrice Weber"/>
            <meta name="citation_author_institution" content="Centre Alexis Vautrin, Vandœuvre lès Nancy, France"/>
      <meta name="citation_author" content="Eric Pujade-Lauraine"/>
            <meta name="citation_author_institution" content="JE2492, Université Paris-Sud, IFR69, Villejuif, France"/>
            <meta name="citation_author_institution" content="Faculté Paris-Descartes, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France"/>
      <meta name="citation_author" content="Sophie Camilleri-Broët"/>
            <meta name="citation_author_institution" content="JE2492, Université Paris-Sud, IFR69, Villejuif, France"/>
            <meta name="citation_author_institution" content="Faculté Paris-Descartes, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France"/>

    <meta name="citation_date" content="2007/11/7"/>

  <meta name="citation_pdf_url" content="http://dx.plos.org/10.1371/journal.pone.0001138.pdf" />

      <meta name="citation_journal_title" content="PLOS ONE" />
    <meta name="citation_firstpage" content="e1138"/>
    <meta name="citation_issue" content="11"/>
    <meta name="citation_volume" content="2"/>
    <meta name="citation_issn" content="1932-6203"/>

    <meta name="citation_journal_abbrev" content="PLoS ONE" />

      <meta name="citation_reference" content="citation_title=Systemic therapy for ovarian cancer: current status and new treatments.; citation_author=RF Ozols; citation_journal_title=Semin Oncol; citation_volume=33; citation_number=1; citation_pages=S3-11; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Untangling the ErbB signalling network.; citation_author=Y Yarden; citation_author=MX Sliwkowski; citation_journal_title=Nat Rev Mol Cell Biol; citation_volume=2; citation_number=2; citation_pages=127-137; citation_date=2001; " />
      <meta name="citation_reference" content="citation_title=Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene.; citation_author=DJ Slamon; citation_author=GM Clark; citation_author=SG Wong; citation_author=WJ Levin; citation_author=A Ullrich; citation_journal_title=Science; citation_volume=235; citation_number=3; citation_pages=177-182; citation_date=1987; " />
      <meta name="citation_reference" content="citation_title=National Cancer Institute of Canada Clinical Trials Group HER2 and responsiveness of breast cancer to adjuvant chemotherapy.; citation_author=KI Pritchard; citation_author=LE Shepherd; citation_author=FP O'Malley; citation_author=IL Andrulis; citation_author=D Tu; citation_author=VH Bramwell; citation_journal_title=N Engl J Med; citation_volume=354; citation_number=4; citation_pages=2103-2111; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.; citation_author=DJ Slamon; citation_author=B Leyland-Jones; citation_author=S Shak; citation_author=H Fuchs; citation_author=V Paton; citation_journal_title=N Engl J Med; citation_volume=344; citation_number=5; citation_pages=783-792; citation_date=2001; " />
      <meta name="citation_reference" content="citation_title=Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.; citation_author=MA Cobleigh; citation_author=CL Vogel; citation_author=D Tripathy; citation_author=NJ Robert; citation_author=S Scholl; citation_journal_title=J Clin Oncol; citation_volume=17; citation_number=6; citation_pages=2639-2648; citation_date=1999; " />
      <meta name="citation_reference" content="citation_title=Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.; citation_author=M Marty; citation_author=F Cognetti; citation_author=D Maraninchi; citation_author=R Snyder; citation_author=L Mauriac; citation_journal_title=J Clin Oncol; citation_volume=23; citation_number=7; citation_pages=4265-4274; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.; citation_author=MJ Piccart-Gebhart; citation_author=M Procter; citation_author=B Leyland-Jones; citation_author=A Goldhirsch; citation_author=M Untch; citation_journal_title=N Engl J Med; citation_volume=353; citation_number=8; citation_pages=1659-1672; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Evaluation of HER2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens; citation_author=MF Press; citation_author=DJ Slamon; citation_author=KJ Flom; citation_author=J Park; citation_author=JY Zhou; citation_journal_title=J Clin Oncol; citation_volume=20; citation_number=9; citation_pages=3095-3105; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study.; citation_author=A Vincent-Salomon; citation_author=G MacGrogan; citation_author=J Couturier; citation_author=L Arnould; citation_author=Y Denoux; citation_journal_title=Histopathology; citation_volume=42; citation_number=10; citation_pages=337-347; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=Best Practice No 176: Updated recommendations for HER2 testing in the UK.; citation_author=IO Ellis; citation_author=J Bartlett; citation_author=M Dowsett; citation_author=S Humphreys; citation_author=B Jasani; citation_journal_title=J Clin Pathol; citation_volume=57; citation_number=11; citation_pages=233-237; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.; citation_author=RR Tubbs; citation_author=JD Pettay; citation_author=PC Roche; citation_author=MH Stoler; citation_author=RB Jenkins; citation_journal_title=J Clin Oncol; citation_volume=19; citation_number=12; citation_pages=2714-2721; citation_date=2001; " />
      <meta name="citation_reference" content="citation_title=HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.; citation_author=EA Perez; citation_author=VJ Suman; citation_author=NE Davidson; citation_author=S Martino; citation_author=PA Kaufman; citation_journal_title=J Clin Oncol; citation_volume=24; citation_number=13; citation_pages=3032-3038; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.; citation_author=AC Wolff; citation_author=ME Hammond; citation_author=JN Schwartz; citation_author=KL Hagerty; citation_author=DC Allred; citation_journal_title=J Clin Oncol; citation_volume=25; citation_number=14; citation_pages=118-145; citation_date=2007; " />
      <meta name="citation_reference" content="citation_title=Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage.; citation_author=TP Singleton; citation_author=T Perrone; citation_author=G Oakley; citation_author=GA Niehans; citation_author=L Carson; citation_journal_title=Cancer; citation_volume=73; citation_number=15; citation_pages=1460-1466; citation_date=1994; " />
      <meta name="citation_reference" content="citation_title=Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression.; citation_author=H Meden; citation_author=D Marx; citation_author=W Rath; citation_author=M Kron; citation_author=A Fattahi-Meibodi; citation_journal_title=Int J Gynecol Pathol; citation_volume=13; citation_number=16; citation_pages=45-53; citation_date=1994; " />
      <meta name="citation_reference" content="citation_title=Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy.; citation_author=E Felip; citation_author=JM Del Campo; citation_author=D Rubio; citation_author=R Vera; citation_author=JM del Campo; citation_journal_title=Cancer; citation_volume=75; citation_number=17; citation_pages=2147-2152; citation_date=1995; " />
      <meta name="citation_reference" content="citation_title=c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis.; citation_author=A Fajac; citation_author=J Benard; citation_author=C Lhomme; citation_author=A Rey; citation_author=P Duvillard; citation_journal_title=Int J Cancer; citation_volume=64; citation_number=18; citation_pages=146-151; citation_date=1995; " />
      <meta name="citation_reference" content="citation_title=ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization.; citation_author=SR Young; citation_author=WH Liu; citation_author=JA Brock; citation_author=ST Smith; citation_journal_title=Genes Chromosomes Cancer; citation_volume=16; citation_number=19; citation_pages=130-137; citation_date=1996; " />
      <meta name="citation_reference" content="citation_title=Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.; citation_author=BA Goff; citation_author=JA Ries; citation_author=LP Els; citation_author=MD Coltrera; citation_author=AM Gown; citation_journal_title=Gynecol Oncol; citation_volume=70; citation_number=20; citation_pages=378-385; citation_date=1998; " />
      <meta name="citation_reference" content="citation_title=Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and HER2/neu expression in ovarian cancer.; citation_author=G Ferrandina; citation_author=FO Ranelletti; citation_author=L Lauriola; citation_author=F Fanfani; citation_author=F Legge; citation_journal_title=Gynecol Oncol; citation_volume=85; citation_number=21; citation_pages=305-310; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.; citation_author=MA Bookman; citation_author=KM Darcy; citation_author=D Clarke-Pearson; citation_author=RA Boothby; citation_author=IR Horowitz; citation_journal_title=J Clin Oncol; citation_volume=21; citation_number=22; citation_pages=283-290; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.; citation_author=EV Hogdall; citation_author=L Christensen; citation_author=SK Kjaer; citation_author=J Blaakaer; citation_author=JE Bock; citation_journal_title=Cancer; citation_volume=98; citation_number=23; citation_pages=66-73; citation_date=2003; " />
      <meta name="citation_reference" content="citation_title=HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group.; citation_author=S Camilleri-Broët; citation_author=AC Hardy-Bessard; citation_author=A Le Tourneau; citation_author=D Paraiso; citation_author=O Levrel; citation_journal_title=Ann Oncol; citation_volume=15; citation_number=24; citation_pages=104-112; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.; citation_author=NG Cloven; citation_author=A Kyshtoobayeva; citation_author=RA Burger; citation_author=IR Yu; citation_author=JP Fruehauf; citation_journal_title=Gynecol Oncol; citation_volume=92; citation_number=25; citation_pages=160-166; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma.; citation_author=TL Erkinheimo; citation_author=H Lassus; citation_author=P Finne; citation_author=BP van Rees; citation_author=A Leminen; citation_journal_title=Clin Cancer Res; citation_volume=10; citation_number=26; citation_pages=538-545; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=TP53 status determines clinical significance of ERBB2 expression in ovarian cancer.; citation_author=J Kupryjanczyk; citation_author=R Madry; citation_author=J Plisiecka-Halasa; citation_author=J Bar; citation_author=E Kraszewska; citation_journal_title=Br J Cancer; citation_volume=91; citation_number=27; citation_pages=1916-1923; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.; citation_author=H Lassus; citation_author=A Leminen; citation_author=A Vayrynen; citation_journal_title=Gynecol Oncol; citation_volume=92; citation_number=28; citation_pages=31-39; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Rates of topoisomerase II-alpha and HER2 gene amplification and expression in epithelial ovarian carcinoma.; citation_author=MS Mano; citation_author=A Awada; citation_author=A Di Leo; citation_author=V Durbecq; citation_author=M Paesmans; citation_journal_title=Gynecol Oncol; citation_volume=92; citation_number=29; citation_pages=887-895; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.; citation_author=JS Nielsen; citation_author=E Jakobsen; citation_author=B Holund; citation_author=K Bertelsen; citation_author=A Jakobsen; citation_journal_title=Int J Gynecol Cancer; citation_volume=14; citation_number=30; citation_pages=1086-1096; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma.; citation_author=CH Lee; citation_author=DG Huntsman; citation_author=MC Cheang; citation_author=RL Parker; citation_author=L Brown; citation_journal_title=Int J Gynecol Pathol; citation_volume=24; citation_number=31; citation_pages=147-152; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance.; citation_author=E Verri; citation_author=P Guglielmini; citation_author=M Puntoni; citation_author=L Perdelli; citation_author=A Papadia; citation_journal_title=Oncology; citation_volume=68; citation_number=32; citation_pages=154-161; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays.; citation_author=D Mayr; citation_author=V Kanitz; citation_author=G Amann; citation_author=J Engel; citation_author=A Burges; citation_journal_title=Histopathology; citation_volume=48; citation_number=33; citation_pages=149-156; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.; citation_author=MF Press; citation_author=G Sauter; citation_author=L Bernstein; citation_author=IE Villalobos; citation_author=M Mirlacher; citation_journal_title=Clin Cancer Res; citation_volume=11; citation_number=34; citation_pages=6598-6607; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas.; citation_author=AP Gouvea; citation_author=F Milanezi; citation_author=SJ Olson; citation_author=D Leitao; citation_author=FC Schmitt; citation_journal_title=Appl Immunohistochem Mol Morphol.; citation_volume=14; citation_number=35; citation_pages=103-8; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.; citation_author=J Couturier; citation_author=A Vincent-Salomon; citation_author=A Nicolas; citation_author=P Beuzeboc; citation_author=E Mouret; citation_journal_title=Mod Pathol; citation_volume=13; citation_number=36; citation_pages=1238-43; citation_date=2000; " />
      <meta name="citation_reference" content="citation_title=Trastuzumab and breast cancer: developments and current status.; citation_author=E Tokunaga; citation_author=E Oki; citation_author=K Nishida; citation_author=T Koga; citation_author=A Egashira; citation_journal_title=Int J Clin Oncol; citation_volume=11; citation_number=37; citation_pages=199-208; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?; citation_author=C Barrett; citation_author=H Magee; citation_author=D O'Toole; citation_author=S Daly; citation_author=M Jeffers; citation_journal_title=J Clin Pathol; citation_volume=60; citation_number=38; citation_pages=690-693; citation_date=2007; " />
      <meta name="citation_reference" content="citation_title=Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.; citation_author=A Serrano-Olvera; citation_author=A Duenas-Gonzalez; citation_author=D Gallardo-Rincon; citation_author=M Candelaria; citation_author=J De la Garza-Salazar; citation_journal_title=Cancer Treat Rev; citation_volume=32; citation_number=39; citation_pages=180-190; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.; citation_author=A Berchuck; citation_author=A Kamel; citation_author=R Whitaker; citation_author=B Kerns; citation_author=G Olt; citation_journal_title=Cancer Res; citation_volume=50; citation_number=40; citation_pages=4087-4091; citation_date=1990; " />
      <meta name="citation_reference" content="citation_title=When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer.; citation_author=H Yamauchi; citation_author=V Stearns; citation_author=DF Hayes; citation_journal_title=J Clin Oncol; citation_volume=19; citation_number=41; citation_pages=2334-2356; citation_date=2001; " />
      <meta name="citation_reference" content="citation_title=Adjuvant docetaxel for node-positive breast cancer.; citation_author=M Martin; citation_author=T Pienkowski; citation_author=J Mackey; citation_author=M Pawlicki; citation_author=JP Guastalla; citation_journal_title=N Engl J Med; citation_volume=352; citation_number=42; citation_pages=2302-2313; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Reversal of HER2 over-expression renders human ovarian cancer cells highly resistant to taxol.; citation_author=A Aigner; citation_author=SS Hsieh; citation_author=C Malerczyk; citation_author=F Czubayko; citation_journal_title=Toxicology; citation_volume=144; citation_number=43; citation_pages=221-228; citation_date=2000; " />

  <link rel="canonical" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001138" />

    <meta name="twitter:card" content="summary"/>
    <meta name="twitter:site" content="@plosone"/>
    <meta name="twitter:title" content="HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients"/>
    <meta name="twitter:description" content="BackgroundDespite a typically good response to first-line combination chemotherapy, the prognosis for patients with advanced ovarian cancer remains poor because of acquired chemoresistance. The use of targeted therapies such as trastuzumab may potentially improve outcomes for patients with ovarian cancer. HER2 overexpression/amplification has been reported in ovarian cancer, but the exact percentage of HER2-positive tumors varies widely in the literature. In this study, HER2 gene status was evaluated in a large, multicentric series of 320 patients with advanced ovarian cancer, including 243 patients enrolled in a multicenter prospective clinical trial of paclitaxel/carboplatin-based chemotherapy.Methodology/Principal FindingsThe HER2 status of primary tumors and metastases was evaluated by both immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analysis of paraffin-embedded tissue on conventional slides. The prognostic impact of HER2 expression was analyzed. HER2 gene was overexpressed and amplified in 6.6% of analyzed tumors. Despite frequent intratumoral heterogeneity, no statistically significant difference was detected between primary tumors and corresponding metastases.Conclusions/SignificanceOur results show that the decision algorithm usually used in breast cancer (IHC as a screening test, with equivocal results confirmed by FISH) is appropriate in ovarian cancer. In contrast to previous series, HER2-positive status did not influence outcome in the present study, possibly due to the fact that patients in our study received paclitaxel/carboplatin-based chemotherapy. This raises the question of whether HER2 status and paclitaxel sensitively are linked."/>
      <meta name="twitter:image" content="http://dx.plos.org/10.1371/journal.pone.0001138.g004"/>

  <meta property="og:title" content="HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients" />
  <meta property="og:type" content="article" />
  <meta property="og:url" content="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001138" />

 <!--end articleInfoX-->

  <link rel="pingback" href="http://www.plosone.org/pingback" />


  <link rel="shortcut icon" href="/images/favicon.ico" type="image/x-icon"/>
  <link rel="home" title="home" href="/"/>
  <link rel="alternate" type="application/rss+xml"
        title="PLOS ONE: New Articles"
        href="http://www.plosone.org/article/feed"/>
</head>
<body>

  <div id="page-wrap">
    <div id="topbanner" class="cf">

<!-- Div for the ad at the top of journal home page-->
<div class="center">
  <div class="title">Advertisement</div>
  <iframe id='a3ac9da4' name='a3ac9da4'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=345&amp;cb=158'
    frameborder='0' scrolling='no' width='730' height='90'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a3ac9da4&amp;cb=892'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=345&amp;cb=4048&amp;n=a3ac9da4'
      border='0' alt=''/>
    </a>
  </iframe>
</div>    </div>

    <div id="pagehdr-wrap">
      <div id="pagehdr">
        <div id="user" class="nav">
          <ul>
            <li><a href="http://www.plos.org">plos.org</a></li>
            <li><a href="https://register.plos.org/ambra-registration/register.action">create account</a></li>
            <li class="btn-style"><a
              href="/user/secure/secureRedirect.action?goTo=%2Farticle%2FfetchArticle.action%3FarticleURI%3Dinfo%253Adoi%252F10.1371%252Fjournal.pone.0001138">sign in</a>
            </li>
          </ul>
        </div>
        <div class="logo">
          <a href="/"><img src="/images/logo.png" alt="PLOS ONE"></a>
        </div>

<div id="nav-main" class="nav">
  <ul>
        <li id="mn-01"><a href="/taxonomy" class="areas-link">Subject Areas</a></li>
    <li id="mn-02"><a href="javascript:void(0);">For Authors</a>
      <div class="submenu" style="width: 540px; margin-left: -300px;">
        <div class="block">
          <div class="submit-script">
            <h3>Submit your Manuscript</h3>
            <ul>
              <li>Fair, rigorous peer review</li>
              <li>Broad scope and wide reach</li>
            </ul>
            <a href="/static/submissionInstructions" class="btn">get started</a>
          </div>
        </div>
        <div class="menu">
          <ul>
            <li><a href="/static/publish">Why Publish with PLOS ONE</a></li>
            <li><a href="/static/publication">Publication Criteria</a></li>
            <li><a href="/static/editorial">Editorial Policies</a></li>
            <li><a href="/static/guidelines">Preparing A Manuscript</a></li>
            <li><a href="/static/figureGuidelines">Figure and Table Guidelines</a></li>
          <li><a href="/static/supportingInformation">Supporting Information Guidelines</a></li>
            <li><a href="/static/submissionInstructions">Submitting a Manuscript</a></li>
          </ul>
        </div>
      </div>
    </li>

    <li id="mn-03"><a href="javascript:void(0);">About Us</a>
      <div class="submenu" style="width:248px; margin-left:-30px;">
        <div class="menu">
          <ul>
            <li><a href="/static/information">Journal Information</a></li>
            <li><a href="/static/edboard">Editorial Board</a></li>
            <li><a href="/static/reviewerGuidelines">Reviewer Guidelines</a></li>
            <li><a href="/static/almInfo">Article-Level Metrics</a></li>
            <li><a href="/static/license">Open-Access License</a></li>
            <li><a href="/static/downloads">Media Downloads</a></li>
            <li><a href="/static/commentGuidelines">Guidelines for Comments</a></li>
            <li><a href="/static/corrections">Corrections</a></li>
            <li><a href="/static/help">Help Using this Site</a></li>
            <li><a href="/static/contact">Contact Us</a></li>
          </ul>
        </div>
      </div>
    </li>
  </ul>
<div id="db">
  <form name="searchForm" action="/search/simple?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0001138" method="get" >
<input type="hidden" name="from" value="globalSimpleSearch" id="from"/><input type="hidden" name="filterJournals" value="PLoSONE" id="filterJournals"/>    <fieldset>
      <legend>Search</legend>
      <label for="search">Search</label>
      <div class="wrap">
        <input id="search" type="text" name="query" placeholder="Search">
        <input type="image" alt="SEARCH" src="/images/icon.search.gif">
      </div>
    </fieldset>
  </form>
    <a id="advSearch" href="/search/advanced?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0001138&filterJournals=PLoSONE">advanced search</a>
</div></div>

      </div>
      <!-- pagehdr-->
    </div>
    <!-- pagehdr-wrap -->

  <!--body and html tags gets closed in global_footer.ftl-->
<script type="text/javascript" src="/javascript/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>

<div id="pagebdy-wrap">
  <div id="pagebdy">

    <div id="article-block" class="cf">

<div class="article-meta cf">
  <ul id="almSignPost" style="display: none;"></ul>
  <div class="article-type">
    <span class="type oa">Open Access</span>
      <span class="type pr">Peer-Reviewed</span>
  </div>
</div>

<div class="header" id="hdr-article">

<div class="article-kicker">
      <span id="article-type-heading">
        Research Article
      </span>
</div>  <h1 property="dc:title" datatype="" rel="dc:type" href="http://purl.org/dc/dcmitype/Text">
    <i>HER2</i> Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
  </h1>

  <ul class="authors">
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Marianne Tuefferd, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  JE2492, Université Paris-Sud, IFR69, Villejuif, France
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Jérôme Couturier, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Service de Génétique Oncologique, Institut Curie, Paris, France
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Frédérique Penault-Llorca, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Departement de Pathologie, Centre Jean Perrin, Clermont-Ferrand, France
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Anne Vincent-Salomon, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Service de Pathologie, Institut Curie, Paris, France
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Philippe Broët, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  JE2492, Université Paris-Sud, IFR69, Villejuif, France
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Jean-Paul Guastalla, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Centre Léon Bérard, Lyon, France
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Djelila Allouache, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Centre François Baclesse, Caen, France
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Martin Combe, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Service de Médecine Interne-Oncologie, Centre Hospitalier, Le Mans, France
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Béatrice Weber, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Centre Alexis Vautrin, Vandœuvre lès Nancy, France
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Eric Pujade-Lauraine, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliations:
                  JE2492, Université Paris-Sud, IFR69, Villejuif, France, 
                  Faculté Paris-Descartes, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Sophie Camilleri-Broët
              <span class="corresponding">mail</span>
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              <p><span class="email">*</span>To whom correspondence should be addressed. E-mail: <a href="mailto:camilleri@vjf.inserm.fr">camilleri@vjf.inserm.fr</a></p>

                <p>Affiliations:
                  JE2492, Université Paris-Sud, IFR69, Villejuif, France, 
                  Faculté Paris-Descartes, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
  </ul>
  <ul class="date-doi-line">
    <li>Published: November 07, 2007</li>
    <li>DOI: 10.1371/journal.pone.0001138</li>
  </ul>


</div><!--end header-->
<div class="main cf" id="pjax-container">
  

<div class="nav items-5" id="nav-article">
  <ul>
  <li>
        <span class="active" name="article">Article</span>
  </li>
  <li>
      <a href="/article/authors/info%3Adoi%2F10.1371%2Fjournal.pone.0001138" name="authors">About the Authors</a>
  </li>
  <li>
      <a href="/article/metrics/info%3Adoi%2F10.1371%2Fjournal.pone.0001138" name="metrics">Metrics</a>
  </li>
  <li>
      <a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0001138" name="comments">Comments</a>
  </li>
  <li>
      <a href="/article/related/info%3Adoi%2F10.1371%2Fjournal.pone.0001138" name="related">Related Content</a>
  </li>
  </ul>
</div>

<script type="text/javascript">
  var selected_tab = "article";
</script>
  <div id="figure-thmbs" class="carousel cf">
    <div class="wrapper">
      <div class="slider">
              <div class="item">
                <a href="#pone-0001138-t001" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.t001" title="Table 1">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.t001&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001138-g001" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.g001" title="Figure 1">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.g001&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001138-g002" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.g002" title="Figure 2">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.g002&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001138-g003" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.g003" title="Figure 3">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.g003&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001138-t002" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.t002" title="Table 2">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.t002&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001138-t003" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.t003" title="Table 3">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.t003&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001138-g004" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.g004" title="Figure 4">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.g004&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
      </div>
    </div>
  </div>

  <div class="nav-col">
    <div class="nav" id="nav-article-page">
      <ul>
        <li class="nav-col-comments"><a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0001138">Reader Comments (1)</a></li>
          <li id="nav-figures"><a data-doi="info:doi/10.1371/journal.pone.0001138" >Figures</a></li>
      </ul>
    </div>
  </div>

  <div class="article">







<div class="abstract"><a id="abstract0" name="abstract0" toc="abstract0" title="Abstract"></a><h2>Abstract</h2>
<h3>Background</h3>
<a id="article1.front1.article-meta1.abstract1.sec1.p1" name="article1.front1.article-meta1.abstract1.sec1.p1"></a><p>Despite a typically good response to first-line combination chemotherapy, the prognosis for patients with advanced ovarian cancer remains poor because of acquired chemoresistance. The use of targeted therapies such as trastuzumab may potentially improve outcomes for patients with ovarian cancer. <em>HER2</em> overexpression/amplification has been reported in ovarian cancer, but the exact percentage of <em>HER2</em>-positive tumors varies widely in the literature. In this study, <em>HER2</em> gene status was evaluated in a large, multicentric series of 320 patients with advanced ovarian cancer, including 243 patients enrolled in a multicenter prospective clinical trial of paclitaxel/carboplatin-based chemotherapy.</p>


<h3>Methodology/Principal Findings</h3>
<a id="article1.front1.article-meta1.abstract1.sec2.p1" name="article1.front1.article-meta1.abstract1.sec2.p1"></a><p>The <em>HER2</em> status of primary tumors and metastases was evaluated by both immunohistochemistry (IHC) and fluorescence <em>in situ</em> hybridization (FISH) analysis of paraffin-embedded tissue on conventional slides. The prognostic impact of <em>HER2</em> expression was analyzed. <em>HER2</em> gene was overexpressed and amplified in 6.6% of analyzed tumors. Despite frequent intratumoral heterogeneity, no statistically significant difference was detected between primary tumors and corresponding metastases.</p>


<h3>Conclusions/Significance</h3>
<a id="article1.front1.article-meta1.abstract1.sec3.p1" name="article1.front1.article-meta1.abstract1.sec3.p1"></a><p>Our results show that the decision algorithm usually used in breast cancer (IHC as a screening test, with equivocal results confirmed by FISH) is appropriate in ovarian cancer. In contrast to previous series, HER2-positive status did not influence outcome in the present study, possibly due to the fact that patients in our study received paclitaxel/carboplatin-based chemotherapy. This raises the question of whether HER2 status and paclitaxel sensitively are linked.</p>

</div>


<div class="articleinfo"><p><strong>Citation: </strong>Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broët P, et al.  (2007) <em>HER2</em> Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients. PLoS ONE 2(11):
          e1138.
            doi:10.1371/journal.pone.0001138</p><p><strong>Academic Editor: </strong>Sui Huang, Children's Hospital Boston, United States of America</p><p><strong>Received:</strong> July 9, 2007; <strong>Accepted:</strong> October 13, 2007; <strong>Published:</strong> November 7, 2007</p><p><strong>Copyright:</strong> © 2007 Tuefferd et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p><p><strong>Funding: </strong>This work was supported by Roche Pharmaceuticals. M. Tuefferd was supported by Janssen Pharmaceutica (Beerse, Belgium).</p><p><strong>Competing interests:</strong> The authors have declared that no competing interests exist.</p></div>





<div id="section1" class="section"><a id="s1" name="s1" toc="s1" title="Introduction"></a><h3>Introduction</h3><a id="article1.body1.sec1.p1" name="article1.body1.sec1.p1"></a><p>Because symptoms are usually absent, 70 to 80% of patients with ovarian cancer will have advanced disease at the time of diagnosis <a href="#pone.0001138-Ozols1">[1]</a>. Despite an initial good response to first-line combination chemotherapy (taxane/platinum), relapses are frequent because of acquired chemoresistance. The use of new targeted therapies that are potentially effective in a subset of patients may be of great value.</p>
<a id="article1.body1.sec1.p2" name="article1.body1.sec1.p2"></a><p><em>HER2</em> (human epidermal growth factor receptor-2) proto-oncogene encodes a protein belonging to the EGFR tyrosine kinase receptor family. Overexpression of <em>HER2</em> initiates intracellular signaling pathways involved in cell proliferation, differentiation, migration and apoptosis <a href="#pone.0001138-Yarden1">[2]</a>. In breast cancer, <em>HER2</em>-positive status is associated with a poor prognosis <a href="#pone.0001138-Slamon1">[3]</a>, and also identifies patients who could benefit from anthracycline-based regimens <a href="#pone.0001138-Pritchard1">[4]</a>.</p>
<a id="article1.body1.sec1.p3" name="article1.body1.sec1.p3"></a><p>Trastuzumab (Herceptin®, F. Hoffmann-La Roche, Basel, Switzerland) is a humanized monoclonal antibody that targets the <em>HER2</em> extracellular domain and inhibits <em>HER2-</em>positive tumor cell proliferation. It is effective alone and in combination with chemotherapy in patients with breast cancer whose tumors express high levels of <em>HER2</em> protein. The benefits of trastuzumab have been demonstrated in both metastatic and adjuvant treatment settings <a href="#pone.0001138-Slamon2">[5]</a>–<a href="#pone.0001138-PiccartGebhart1">[8]</a>.</p>
<a id="article1.body1.sec1.p4" name="article1.body1.sec1.p4"></a><p>Accurate evaluation of <em>HER2</em> status is essential for optimal patient selection for trastuzumab. Among the numerous methods published, immunohistochemistry (IHC) and fluorescence <em>in situ</em> hybridization (FISH) are the most widely used and have high reported concordance <a href="#pone.0001138-Press1">[9]</a>–<a href="#pone.0001138-VincentSalomon1">[10]</a>. FISH has been shown to more accurately select patients than IHC, but is more costly and not routinely available. The recommended algorithm for <em>HER2</em> determination in breast cancer is to use IHC initially, using a semi-quantitative scoring system followed by FISH for 2+ ambiguous samples <a href="#pone.0001138-Ellis1">[11]</a>–<a href="#pone.0001138-Wolff1">[14]</a>.</p>
<a id="article1.body1.sec1.p5" name="article1.body1.sec1.p5"></a><p>Observed rates of <em>HER2</em> overexpression/amplification in ovarian carcinomas show considerable variation between studies, ranging from 8% to 66% <a href="#pone.0001138-Singleton1">[15]</a>–<a href="#pone.0001138-Mayr1">[33]</a>. Single-agent trastuzumab therapy was associated with a low response rate (7%) in a series of heavily pretreated patients with ovarian cancer <a href="#pone.0001138-Bookman1">[22]</a>, but the efficacy of trastuzumab in combination with chemotherapy has not been tested in this setting.</p>
<a id="article1.body1.sec1.p6" name="article1.body1.sec1.p6"></a><p>The aim of the current study was to determine the proportion of patients with advanced ovarian cancer whose tumors were <em>HER2</em>-positive. This was assessed using conventional slides from both primary tumors and metastases and applying reference <em>HER2</em> screening algorithm for breast tumors, to discriminate equivocal and heterogeneous staining.</p>
</div>

<div id="section2" class="section"><a id="s2" name="s2" toc="s2" title="Methods"></a><h3>Methods</h3>
<h4>Participants</h4>
<a id="article1.body1.sec2.sec1.p1" name="article1.body1.sec2.sec1.p1"></a><p>Three hundred and twenty patients with advanced primary ovarian carcinomas (International Federation of Gynecology and Obstetrics [FIGO] stage Ic–IV) or primary peritoneal carcinomas were included. Of these, 243 (75.9%) had been enrolled in a larger phase III GERCOR-AGO-OVAR-9 randomized trial of first-line paclitaxel/carboplatin/gemcitabine (TCG) chemotherapy, conducted in 58 centers between July 2002 and April 2004 [ClinicalTrials.gov Identifier: NCT00052468]. The clinical characteristics of patients include in the TCG trial are presented in <a href="#pone-0001138-t001">Table 1</a>. The 77 remaining patients (56 centers) included in our analysis demonstrated paclitaxel/carboplatin chemoresistance (defined as progression during therapy or relapse within 6 months after completing therapy).</p>
<div class="figure" id="pone-0001138-t001"><div class="img"><a name="pone-0001138-t001" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.t001&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.t001"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.t001&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.t001/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.t001/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.t001/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.t001/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001138.t001.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.t001/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.t001/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001138.t001.TIF"></span>)
                </a></li></ul></div><p><strong>Table 1.  <span>Characteristics of 243 patients included in the phase III TCG trial</span></strong></p><span>doi:10.1371/journal.pone.0001138.t001</span></div>

<h4>Ethics</h4>
<a id="article1.body1.sec2.sec2.p1" name="article1.body1.sec2.sec2.p1"></a><p>The study was approved by the local ethical committee (CCPPRB number: 02780) and all individual patients gave written informed consent for biological studies.</p>


<h4><em>HER2</em> determination by IHC</h4>
<a id="article1.body1.sec2.sec3.p1" name="article1.body1.sec2.sec3.p1"></a><p>Formalin-fixed and paraffin-embedded tumors from primary surgery were obtained retrospectively. Because of previously reported heterogeneity in <em>HER2</em> expression in ovarian cancer <a href="#pone.0001138-CamilleriBrot1">[24]</a>, in the present study we chose to analyze four blocks containing tumor: two blocks of primary tumors and two blocks of chemo-naïve metastases/peritoneal dissemination (available from 206 patients). Most of the metastases analyzed were peritoneal dissemination, whereas few corresponded to lymph node sections.</p>
<a id="article1.body1.sec2.sec3.p2" name="article1.body1.sec2.sec3.p2"></a><p>Following deparaffinization and rehydration, the 4 µm sections were microwave pretreated in pH 6 citrate buffer. Primary antibody (CB-11, Novocastra, Newcastle-upon-Tyne, UK) diluted 1/800 was incubated for 2 hours. Staining was achieved using a streptavidin-biotin-peroxidase kit (Abcys, Biospa, Milano, Italy) including 30-minute incubation for each step. Nuclei were counterstained with haematoxylin. <em>HER2</em> positivity was assessed using Ellis and Wolff recommendations <a href="#pone.0001138-Wolff1">[14]</a>,<a href="#pone.0001138-Cloven1">[25]</a>. A score of 1+ was defined as barely perceptible membrane staining in more than 10% of cells, a score of 2+ was defined as weak-to-moderate complete membrane with staining present in more than 10% of tumor cells, and a score of 3+ was defined as strong complete membrane staining in more than 10% of tumor cells. We classified 2+ as equivocal and 3+ as positive. Cytoplasmic staining was considered to be non-specific. For each case, an external control containing two FISH-positive (2+/3+) breast cancer samples was used.</p>


<h4><em>HER2</em> determination by FISH</h4>
<a id="article1.body1.sec2.sec4.p1" name="article1.body1.sec2.sec4.p1"></a><p>All samples of 2+/3+ <em>HER2</em> protein expression and 24 samples with 0/1+ staining score were evaluated by FISH, performed on a single block in one of the following laboratories, according to local instutitional procedures: Institut Curie, Paris (PathVysion <em>HER2</em> kit; Abbott-Vysis, Desplaines, IL); Centre Jean Perrin, Clermont-Ferrand (PathVysion <em>HER2</em> kit; Vysis, IL); Hôtel-Dieu, Paris, (<em>HER2</em> kit, DakoCytomation, Glostrup, Denmark). Instructions from the test kit manufacturers were followed, with slight modifications.</p>
<a id="article1.body1.sec2.sec4.p2" name="article1.body1.sec2.sec4.p2"></a><p>Four µm deparaffinized sections were incubated in pretreatment buffer at 95°C for 15 minutes, then in proteolytic solution at 37°C for 5 minutes. Co-denaturation of the probe and DNA of the tissue section was achieved by incubation at 82°C for 5 minutes using a HyBrite device (Abbott-Vysis) ; this was followed by a 15-hour hybridization at 37°C. Post-hybridization washes were performed according to the respective protocols. Slides were mounted in DAPI/antifade and viewed with a fluorescent microscope. Sixty nuclei in several areas of the section were analyzed, and three representative images per case were captured. Tumors were classified as amplified if they showed a mean of ≥8 <em>HER2</em> signals, or a <em>HER2</em>/centromere 17 ratio &gt;2.2 in samples of fewer than 8 <em>HER2</em> signals.</p>


<h4>Statistics</h4>
<a id="article1.body1.sec2.sec5.p1" name="article1.body1.sec2.sec5.p1"></a><p>The study was designed to evaluate <em>HER2</em> status in a population of patients with advanced ovarian cancer. <em>HER2</em> status in primary tumors and metastases was compared using kappa testing. The relationship between clinical characteristics of the 243 patients included in the TCG trial and <em>HER2</em> status was compared using chi-square testing. Overall survival (OS) was calculated from the date of inclusion to death and progression-free survival (PFS) was calculated from the date of inclusion until progression or last follow-up examination. Progression was defined as a 20% increase in the diameter of all measured lesions, appearance of new lesions and/or doubling from baseline of CA125 tumor marker concentration. OS and PFS curves were derived from Kaplan-Meier estimates. A univariate Cox model analysis was performed to estimate and test the prognostic influence of clinical and biological variables. In a multivariate analysis, the Cox proportional hazard regression model was applied to determine the influence of these variables on outcome, adjusted for other prognostic factors. Hazard ratios (HR) and 95% confidence intervals (CI) were determined. The influence of <em>HER2</em> status in drug-resistant ovarian cancer was assessed in a subset of 109 patients with FIGO stage IIIc -IV disease and sub-optimal surgery. The resistant group was defined as presenting a first progression during or within 6 months following the end of treatment. The sensitive group was defined as non-progressive patients within the year after the end of treatment. <em>HER2</em> status between resistant and sensitive groups was evaluated using exact Fisher testing. <em>P</em> values ≤0.05 were considered significant. All analyses were performed using SPlus software (Insightful, Seattle, WA).</p>

</div>

<div id="section3" class="section"><a id="s3" name="s3" toc="s3" title="Results"></a><h3>Results</h3>
<h4><em>HER2</em> overexpression</h4>
<a id="article1.body1.sec3.sec1.p1" name="article1.body1.sec3.sec1.p1"></a><p>Of the 320 tumors analyzed, <em>HER2</em> 3+ staining was observed in 15 samples (4.7%) and 2+ in 26 samples (8.1%) (<a href="#pone-0001138-g001">Figure 1</a>). <em>HER2</em> expression of 0 or 1+ was detected in the 279 remaining samples (87.2%). One-third of tumors showed some intracytoplasmic staining, considered as non-specific (data not shown). Among the 41 samples with 2+/3+ staining, 19 (46.3%) were heterogeneous and the same pattern was seen in the metastatic samples.</p>
<div class="figure" id="pone-0001138-g001"><div class="img"><a name="pone-0001138-g001" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.g001&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.g001"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.g001&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.g001/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.g001/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.g001/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.g001/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001138.g001.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.g001/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.g001/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001138.g001.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 1.  <span>Immunohistochemistry labeling results.</span></strong></p><a id="article1.body1.sec3.sec1.fig1.caption1.p1" name="article1.body1.sec3.sec1.fig1.caption1.p1"></a><p>A. 2+ score: weak-to-moderate complete membrane staining in more than 10% of tumor cells (objX40). B. 3+ score: strong complete membrane staining in more than 10% of tumour cells (objX40). C. Heterogeneous staining of a primary ovarian tumour (objX20). D: Heterogeneous staining of a metastasis (objX20) E. FISH: heterogeneous amplification of <em>HER2</em> in a tumor showing a cluster of tumor cells with amplification (white arrow, left part) and a cluster of non amplified tumor cells (orange arrow, right part). F: Clusters of red spots (<em>HER2</em> amplification) together with two green spots (centromere 17).</p>
<span>doi:10.1371/journal.pone.0001138.g001</span></div><a id="article1.body1.sec3.sec1.p2" name="article1.body1.sec3.sec1.p2"></a><p>Of the 206 patients from whom both primary tumor and distant metastatic samples were available, there was concordance between primary tumor and metastases in 197 samples (95.6%; 179 negative and 18 positive). No statistical difference between <em>HER2</em> overexpression in primary tumors and corresponding metastases could be identified by kappa testing. In nine samples, 2+/3+ <em>HER2</em> staining was found exclusively in either primary tumor (five samples) or metastases (four samples). Three of these nine samples showed 3+ overexpression and were amplified. The six remaining samples showed 2+ expression and one of these showed <em>HER2</em> gene amplification by FISH.</p>


<h4><em>HER2</em> gene amplification</h4>
<a id="article1.body1.sec3.sec2.p1" name="article1.body1.sec3.sec2.p1"></a><p>Sixty-five samples were analyzed by FISH for <em>HER2</em> amplification, including all of the 26 equivocal (2+) tumors, the 15 positive (3+) tumors, and 24 samples showing 1+ or cytoplasmic staining. Three samples (two with 2+ and one with 3+ staining) were not evaluable because of DNA alteration by fixation, despite two attempts conducted in two laboratories. Thus a total of 62 samples were evaluated by FISH (<a href="#pone-0001138-g002">Figure 2</a>). In total 21 patients showed <em>HER2</em> positive status (all of the samples with IHC 3+ score and 6 of 24 samples with IHC 2+ score validated by FISH). None of the 24 samples with 1+ or cytoplasmic positivity was amplified for <em>HER2</em>.</p>
<div class="figure" id="pone-0001138-g002"><div class="img"><a name="pone-0001138-g002" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.g002&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.g002"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.g002&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.g002/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.g002/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.g002/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.g002/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001138.g002.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.g002/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.g002/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001138.g002.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 2.  <span><em>HER2</em> gene amplification repartition according to <em>HER2</em> protein status.</span></strong></p><a id="article1.body1.sec3.sec2.fig1.caption1.p1" name="article1.body1.sec3.sec2.fig1.caption1.p1"></a><p>Perfect concordance in protein expression and gene amplification has been observed for samples with 3+ or 0/1+ IHC staining. In our study, 25% of equivocal samples (IHC 2+ staining) were amplified for <em>HER2</em> gene. Based on the HER2 reference scoring algorithm, 21 samples were considered as positive (15 scored 3+ by IHC and 6 scored 2+ validated by FISH). Three samples could not be compared by FISH due to fixation (one 3+ and two 2+ IHC scored). IHC = immunohistochemistry; FISH = fluorescence <em>in situ</em> hybridization.</p>
<span>doi:10.1371/journal.pone.0001138.g002</span></div><a id="article1.body1.sec3.sec2.p2" name="article1.body1.sec3.sec2.p2"></a><p>In the heterogeneous samples, <em>HER2</em> overexpression and amplification were found in the same tumor areas. Eighteen of 21 samples with <em>HER2</em> amplification showed more than 8 copies per tumor nucleus with large clusters, suggesting homogeneous staining regions. The three remaining samples showed amplification with 8–10 copies per tumor nucleus, and a significant <em>HER2</em>/centromere 17 ratio.</p>


<h4>Relationship between biological markers and other prognostic variables</h4>
<a id="article1.body1.sec3.sec3.p1" name="article1.body1.sec3.sec3.p1"></a><p>No relationship between <em>HER2</em> status and other prognostic factors (tumor stage, histological type, grade, ascites, debulking status, age and performance status) was found.</p>


<h4>Survival analysis</h4>
<a id="article1.body1.sec3.sec4.p1" name="article1.body1.sec3.sec4.p1"></a><p>Median follow-up was 24.9 months (95% CI: 23.4–26.3). At the time of our analysis (July 2006), disease progression had occurred in 150 (61.7%) patients and 66 (27.2%) had died. Median PFS duration was 17.7 months (95% CI: 15.3–20.6). Median OS had not been reached. Among the 41 patients whose tumor was 2+/3+ by IHC, disease progressed in 18 (43.9%) and there were seven (17.1%) deaths, while in the group of 16 patients with <em>HER2</em> amplification, disease progressed in 12 (75%) and there were four (25%) deaths (<a href="#pone-0001138-g003">Figure 3</a>).</p>
<div class="figure" id="pone-0001138-g003"><div class="img"><a name="pone-0001138-g003" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.g003&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.g003"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.g003&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.g003/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.g003/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.g003/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.g003/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001138.g003.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.g003/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.g003/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001138.g003.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 3.  <span>Progression-free survival and overall survival according to <em>HER2</em> status.</span></strong></p><a id="article1.body1.sec3.sec4.fig1.caption1.p1" name="article1.body1.sec3.sec4.fig1.caption1.p1"></a><p>A. Progression-free survival B. Overall survival</p>
<span>doi:10.1371/journal.pone.0001138.g003</span></div>

<h4>Univariate analysis</h4>
<a id="article1.body1.sec3.sec5.p1" name="article1.body1.sec3.sec5.p1"></a><p>Univariate analysis of the potential prognostic impact of clinical and histopathological parameters identified performance status 1 or 2, tumor stage, ascites and residual tumor after first laparotomy as significantly associated with shorter OS and PFS (<a href="#pone-0001138-t002">Table 2</a>). The association between age ≥ 60 years and poorer OS was borderline significant. <em>HER2</em> status (evaluated by either IHC or FISH) was not of prognostic value in terms of OS and PFS.</p>
<div class="figure" id="pone-0001138-t002"><div class="img"><a name="pone-0001138-t002" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.t002&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.t002"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.t002&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.t002/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.t002/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.t002/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.t002/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001138.t002.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.t002/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.t002/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001138.t002.TIF"></span>)
                </a></li></ul></div><p><strong>Table 2.  <span>Univariate analysis for progression-free survival and overall survival of biological and clinical parameters</span></strong></p><span>doi:10.1371/journal.pone.0001138.t002</span></div>

<h4>Multivariate analysis</h4>
<a id="article1.body1.sec3.sec6.p1" name="article1.body1.sec3.sec6.p1"></a><p>Age, performance status, FIGO stage, ascites, residual tumor after first laparotomy and <em>HER2</em> amplification/overexpression status were considered. Only the presence of ascites was retained as an independent prognostic factor of both shorter PFS (<em>P</em> = 0.037) and OS (<em>P</em> = 0.016) (<a href="#pone-0001138-t003">Table 3</a>). High FIGO stage was also retained as a prognostic factor for PFS (<em>P</em> = 0.00041) alone. <em>HER2</em> status had no significant impact.</p>
<div class="figure" id="pone-0001138-t003"><div class="img"><a name="pone-0001138-t003" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.t003&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.t003"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.t003&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.t003/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.t003/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.t003/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.t003/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001138.t003.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.t003/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.t003/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001138.t003.TIF"></span>)
                </a></li></ul></div><p><strong>Table 3.  <span>Multivariate analysis of clinical parameters for progression-free survival and overall survival</span></strong></p><span>doi:10.1371/journal.pone.0001138.t003</span></div>

<h4>Chemoresistance and <em>HER2</em> status</h4>
<a id="article1.body1.sec3.sec7.p1" name="article1.body1.sec3.sec7.p1"></a><p>From the cohort of patients included in the TCG trial, a subset of 109 patients with FIGO stage IIIc/IV primary tumor and sub-optimal surgery was selected for analysis. Based on follow-up, 46 patients were considered as chemoresistant, 36 as chemosensitive, and 27 could not be classified in one of the two groups. <em>HER2</em> status was not significantly linked to chemoresistant status.</p>

</div>

<div id="section4" class="section"><a id="s4" name="s4" toc="s4" title="Discussion"></a><h3>Discussion</h3><a id="article1.body1.sec4.p1" name="article1.body1.sec4.p1"></a><p>In this study, we screened 320 advanced ovarian cancers for <em>HER2</em> status. To our knowledge, this is the first large multicentric study investigating both primary tumor and metastases on conventional slides by IHC and FISH techniques. Positive <em>HER2</em> status was found in 6.6% (21 of 320) of the tumor samples. The rate of <em>HER2</em> positivity varies in the literature from 8% to 66% <a href="#pone.0001138-Singleton1">[15]</a>–<a href="#pone.0001138-Mayr1">[33]</a> (<a href="#pone-0001138-g004">Figure 4</a>). There are several possible explanations for the wide variation and the relatively low rate of <em>HER2</em> positivity reported in our series, including the different detection methods used (IHC, FISH and chromogenic <em>in situ</em> hybridization), different sources of material (blocks of tumors and tissue microarray), and variations in IHC assay techniques (CB-11, HercepTest or a non-commercial antibody); in addition, variance in staining protocols and subjective interpretation of sample stains makes direct comparison of studies difficult. The present study has the advantage of being based on a large, prospective, multicenter trial, with extensive tumor sampling (four conventional slides of tumor/metastases when available). Moreover, all of the positive/doubtful samples (IHC 1+, 2+, 3+ and those with cytoplasmic staining) were analyzed by FISH. The rate of <em>HER2</em> protein overexpression (2+/3+ by IHC) was 13% in the present series, whereas it varied from 1.9% to 35% in previous reports. We used the CB-11 monoclonal antibody, which has been shown to be more accurate than HercepTest, the other widely used, Food and Drug Administration (FDA)-approved antibody <a href="#pone.0001138-Tubbs1">[12]</a>, <a href="#pone.0001138-Press2">[34]</a>, and to show better concordance with FISH (<a href="#pone.0001138-Ellis1">[11]</a>, <a href="#pone.0001138-Gouvea1">[35]</a>). To our knowledge, no cross-reactivity with other EGFR family protein has been reported using this antibody <a href="#pone.0001138-Lee1">[31]</a>. We adapted our IHC assay according to Couturier et al. <a href="#pone.0001138-Couturier1">[36]</a> with a dilution of the primary antibody (1/800), since this procedure has shown a complete concordance with gene amplification assessed by FISH. Our results confirm the good concordance between IHC and FISH analyses in ovarian cancers because all the samples showing 1+ staining or cytoplasmic staining were not amplified, thus excluding the hypothesis of possible false negatives. It is worth noting that <em>HER2</em> testing procedures have evolved with time, resulting in a more consistent rate of positive cases (11–16%) in most of the recent studies.</p>
<div class="figure" id="pone-0001138-g004"><div class="img"><a name="pone-0001138-g004" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.g004&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001138" data-uri="info:doi/10.1371/journal.pone.0001138.g004"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001138.g004&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.g004/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.g004/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.g004/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.g004/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001138.g004.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001138.g004/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001138.g004/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001138.g004.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 4.  <span><em>HER2</em> in major published studies.</span></strong></p><a id="article1.body1.sec4.fig1.caption1.p1" name="article1.body1.sec4.fig1.caption1.p1"></a><p>A. Overexpression Review of selected articles evaluating <em>HER2</em> protein expression in large series of patients (including more than 50 tumour samples) published in international journals after 1994. Boxes represent % of <em>HER2</em> overexpression (scored as 2+ or 3+) and error bars show ±2 standard errors for each study. B. IHC and FISH status Review of selected articles evaluating <em>HER2</em> gene amplification (FISH or CISH) and/or <em>HER2</em> protein expression in large series of patients (including more than 50 tumour samples) published in international journals after 1994.<em>In situ</em> hybridisation represents FISH (fluorescence <em>in situ</em> hybridisation) and CISH (chromogenic <em>In situ</em> hybridisation) results. Mean <em>HER2</em> overexpression/amplification across studies is represented; IHC = Immunohistochemistry.</p>
<span>doi:10.1371/journal.pone.0001138.g004</span></div><a id="article1.body1.sec4.p2" name="article1.body1.sec4.p2"></a><p>Compared with the 20–30% rate of <em>HER2</em> positivity observed in breast cancers <a href="#pone.0001138-Press2">[34]</a>, <a href="#pone.0001138-Tokunaga1">[37]</a>, the rate in ovarian cancer is lower and intratumoral heterogeneity is frequently detected. The good concordance between <em>HER2</em> status in primary tumor and corresponding distant locations suggests that <em>HER2</em> clonal selection occurs before tumor dissemination. It is worth noting that some tumors showed the same heterogeneous pattern in both primary and distant locations with adjacent positive and negative areas, detected by both IHC and FISH methods.</p>
<a id="article1.body1.sec4.p3" name="article1.body1.sec4.p3"></a><p>We observed a good correlation between IHC and FISH results for no/weak (0/1+) and strong (3+) IHC scores, whereas only 25% of the IHC 2+ samples were found to be amplified by FISH testing. A similar rate has been reported in breast cancer <a href="#pone.0001138-VincentSalomon1">[10]</a>, <a href="#pone.0001138-Barrett1">[38]</a>. Moreover, it has been shown that among 2+ IHC false positive cases, none overexpressed HER2 mRNA as mesured by in situ hybridization <a href="#pone.0001138-Tubbs1">[12]</a>. Our results show that the decision algorithm currently used in breast cancers (IHC as a screening test, with equivocal results confirmed by FISH) is appropriate in ovarian cancers. <em>HER2</em> amplification/overexpression is associated with poor prognosis in several cancer types, and its prognostic value in ovarian cancer has been reviewed recently by Serrano-Olvera et al. <a href="#pone.0001138-SerranoOlvera1">[39]</a>. An adverse prognostic impact of <em>HER2</em> overexpression and/or amplification has been shown in most of the published series <a href="#pone.0001138-Slamon1">[3]</a>, <a href="#pone.0001138-Meden1">[16]</a>–<a href="#pone.0001138-Fajac1">[18]</a>, <a href="#pone.0001138-Hogdall1">[23]</a>, <a href="#pone.0001138-Kupryjanczyk1">[27]</a>, <a href="#pone.0001138-Lassus1">[28]</a>, <a href="#pone.0001138-Nielsen1">[30]</a>, <a href="#pone.0001138-Verri1">[32]</a>, <a href="#pone.0001138-Berchuck1">[40]</a>, including one reported by our group <a href="#pone.0001138-CamilleriBrot1">[24]</a>. In the present study, we did not identify any prognostic value of <em>HER2</em> status. In contrast to our previous study <a href="#pone.0001138-CamilleriBrot1">[24]</a>, patients in the present series received paclitaxel-based chemotherapy, raising the question of a possible interaction between <em>HER2</em> positivity and drug sensitivity. The clinical impact of <em>HER2</em> status on the response to paclitaxel has been suggested, but a significant association has not been shown <a href="#pone.0001138-Yamauchi1">[41]</a>–<a href="#pone.0001138-Martin1">[42]</a>. Interestingly, <em>in vitro</em> studies in the SK-OV-3 ovarian cancer cell line showed that sensitivity to paclitaxel dramatically increased in cells expressing high levels of <em>HER2</em> <a href="#pone.0001138-Aigner1">[43]</a>. Since HER2-positive cells are likely dividing rapidly, they may be more sensitive to paclitaxel-based chemotherapy. Altogether, these results suggest that paclitaxel may overcome the poor prognosis associated with <em>HER2</em> positivity targeting dividing cells.</p>
</div>





<div><a id="ack" name="ack" toc="ack" title="Acknowledgments"></a><h3>Acknowledgments</h3>
<a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1"></a><p>The authors thank P. Bonjour-Guernalec, F. Devez, V. Ducruit and B. Marmey, for expert technical assistance. The authors wish to acknowledge the following investigators: C. Boiron, J. Cretin, H. Cure, J.M. Rodier, and the following pathologists: I. Abd Alsamad, A. Albouy, F. Allias, M. Amin, E. Anger, F. Arbion, E. Auberger, M. Augros, M.L. Auriault, A.C. Baglin, M.C. Baranzelli, D. Barrès, G. Beau, L. Benard, S. Benjaballah, N. BenLagha, G. Bertrand, C. Bertrand-Exbrayat, H. Bibas, M.C. Bidabié, H. Bizollon, K.I. Bland, F. Boidart, J.F. Boivin, X. Bonniere, E. Bonte, C. Bor, R. Bosc, G. Botero-Constant, M. Bouc, I. Brocheriou, A. Buénard, V. Cahn, C.S. Castelain, C. Cavailles, M.C. Chapeau, J. Chasle, A. Chevallier, L. Choudat, C. Cohen-Pansieri, F. Comoz, E. Constancis, O. Coué, C. Creusy, A. Croué, J. d'Anjou, A. Daubech, C. David, C. DeBaecque, C. Debiais, F. de Kergal, Y. Denoux, F. de Queiroz, L.R. de Ybarlucea, H.G. Digneton, G. Dubost, T. Ducastelle, A. Dupays, P. Dupin, A. Economides, M.O. Farine, E. Faure, M. Faÿsse, M. Felce-Dachez, M. Fery, C. Fleury, D. Fremaux, N. Froment, F. Galteau, F. Gasnier, P. Genin, P. Gentil, A. Gentil Perret, F. Gerard, H. Gerard, E. Gestin, P.M. Girardot, M.C. Golaire, J.M. Goujon, P. Granger, J. Grémain, F. Guihaume, H. Guyot, N. Hamhrit, A. Hana-Luca, J.F. Henninger, J.P. Herve de Sigalony, T. Homsi, S. Houissa Vuong, D. Hugol, S. Isaac, C. Jeanne-Pasquier, Y. Jeffredo, J. Kapfer, M. Kassem, P. Kermanach, S. Kettani, A-M. Khadi, I. Kleinclaus, S. Kowalski, C. Laboisse, C. Lassabe, C. Lauro-Colleaux, E. Lavoine, M. Lazarotto-Rumpler, C. Lefort, M-A. Lefrère-Belda, C. Legendre, M. Le Pahun, A. Leroux, P. Levillain, M-J. Loyer Lecestre, J.P. Mackayakhi, C. Magois, M. Maisonneuve, T. Malard, M-F. Marck, B. Marie, J.M. Massot-Bordenave, A. Mechine Neuville, D. Mêmeteau, C. Memeu, D Menzies , J.J. Michiels, C. Migeon, C. Monin, C. Muller, J. Muller, A. Neuville, C. Normand, C. Pallud, D. Panthou, P. Papazian, A. Pasquiou, B. Petit, F. Petit, D. Petrot, M. Piche, A. Pilon, M. Pizzi-Anselme, P. Pocachard, M. Poilpré, G. Pugens, M. Rabreau, J. Raffoul, P. Raffy, M.C. RaymondGelle, O. Renaud, C. Richard, I. Roche-Comet, L. Roquet, C. Sagan, A. Sautet, F. Serain, P. Seurat, L. Siché, C. Souche, A. Soulier, N. Terrier, J. Thevenot, P. Tranbaloc, M. Trassard, E. Vaneenoge, R. Vergez-Pascal, S. Visée, F. Walker, and L. Zemoura.</p>
</div><div class="contributions"><a id="authcontrib" name="authcontrib" toc="authcontrib" title="Author Contributions"></a><h3>Author Contributions</h3><p>Conceived and designed the experiments: EP SC. Performed the experiments: Jc FP AV SC. Analyzed the data: MT SC. Contributed reagents/materials/analysis tools: Jc FP AV JG DA MC BW EP SC. Wrote the paper: MT SC. Other: Principal investigator: BW MC DA JG. Supervised data analysis: PB.</p></div><div><a id="references" name="references" toc="references" title="References"></a><h3>References</h3><ol class="references"><li><span class="label">1.
              </span><a name="pone.0001138-Ozols1" id="pone.0001138-Ozols1"></a>Ozols RF (2006) Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol  33: S3–11.  <ul class="find" data-citedArticleID="1014332" data-doi="10.1053/j.seminoncol.2006.03.011"><li><a href="http://dx.doi.org/10.1053/j.seminoncol.2006.03.011" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Systemic+therapy+for+ovarian+cancer%3A+current+status+and+new+treatments." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Systemic+therapy+for+ovarian+cancer%3A+current+status+and+new+treatments.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">2.
              </span><a name="pone.0001138-Yarden1" id="pone.0001138-Yarden1"></a>Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol  2: 127–137.  <ul class="find" data-citedArticleID="1014364" data-doi="10.1038/35052073"><li><a href="http://dx.doi.org/10.1038/35052073" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Untangling+the+ErbB+signalling+network." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Untangling+the+ErbB+signalling+network.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">3.
              </span><a name="pone.0001138-Slamon1" id="pone.0001138-Slamon1"></a>Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al.  (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science  235: 177–182.  <ul class="find" data-citedArticleID="1014348" data-doi="10.1126/science.3798106"><li><a href="http://dx.doi.org/10.1126/science.3798106" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Human+breast+cancer%3A+correlation+of+relapse+and+survival+with+amplification+of+the+HER2%2Fneu+oncogene." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Human+breast+cancer%3A+correlation+of+relapse+and+survival+with+amplification+of+the+HER2%2Fneu+oncogene.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">4.
              </span><a name="pone.0001138-Pritchard1" id="pone.0001138-Pritchard1"></a>Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, et al.  (2006) National Cancer Institute of Canada Clinical Trials Group HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med  354: 2103–2111.  <ul class="find" data-citedArticleID="1014342" data-doi="10.1056/nejmoa054504"><li><a href="http://dx.doi.org/10.1056/nejmoa054504" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=National+Cancer+Institute+of+Canada+Clinical+Trials+Group+HER2+and+responsiveness+of+breast+cancer+to+adjuvant+chemotherapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22National+Cancer+Institute+of+Canada+Clinical+Trials+Group+HER2+and+responsiveness+of+breast+cancer+to+adjuvant+chemotherapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">5.
              </span><a name="pone.0001138-Slamon2" id="pone.0001138-Slamon2"></a>Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al.  (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med  344: 783–792.  <ul class="find" data-citedArticleID="1014350" data-doi="10.1056/nejm200103153441101"><li><a href="http://dx.doi.org/10.1056/nejm200103153441101" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Use+of+chemotherapy+plus+a+monoclonal+antibody+against+HER2+for+metastatic+breast+cancer+that+overexpresses+HER2." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Use+of+chemotherapy+plus+a+monoclonal+antibody+against+HER2+for+metastatic+breast+cancer+that+overexpresses+HER2.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">6.
              </span><a name="pone.0001138-Cobleigh1" id="pone.0001138-Cobleigh1"></a>Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al.  (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol  17: 2639–2648.  <ul class="find" data-citedArticleID="1014294"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Multinational+study+of+the+efficacy+and+safety+of+humanized+anti-HER2+monoclonal+antibody+in+women+who+have+HER2-overexpressing+metastatic+breast+cancer+that+has+progressed+after+chemotherapy+for+metastatic+disease.&amp;auth=&amp;atitle=Multinational+study+of+the+efficacy+and+safety+of+humanized+anti-HER2+monoclonal+antibody+in+women+who+have+HER2-overexpressing+metastatic+breast+cancer+that+has+progressed+after+chemotherapy+for+metastatic+disease." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Multinational+study+of+the+efficacy+and+safety+of+humanized+anti-HER2+monoclonal+antibody+in+women+who+have+HER2-overexpressing+metastatic+breast+cancer+that+has+progressed+after+chemotherapy+for+metastatic+disease." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Multinational+study+of+the+efficacy+and+safety+of+humanized+anti-HER2+monoclonal+antibody+in+women+who+have+HER2-overexpressing+metastatic+breast+cancer+that+has+progressed+after+chemotherapy+for+metastatic+disease.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">7.
              </span><a name="pone.0001138-Marty1" id="pone.0001138-Marty1"></a>Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, et al.  (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol  23: 4265–4274.  <ul class="find" data-citedArticleID="1014324" data-doi="10.1200/jco.2005.04.173"><li><a href="http://dx.doi.org/10.1200/jco.2005.04.173" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Randomized+phase+II+trial+of+the+efficacy+and+safety+of+trastuzumab+combined+with+docetaxel+in+patients+with+human+epidermal+growth+factor+receptor+2-positive+metastatic+breast+cancer+administered+as+first-line+treatment%3A+the+M77001+study+group." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Randomized+phase+II+trial+of+the+efficacy+and+safety+of+trastuzumab+combined+with+docetaxel+in+patients+with+human+epidermal+growth+factor+receptor+2-positive+metastatic+breast+cancer+administered+as+first-line+treatment%3A+the+M77001+study+group.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">8.
              </span><a name="pone.0001138-PiccartGebhart1" id="pone.0001138-PiccartGebhart1"></a>Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al.  (2005) Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med  353: 1659–1672.  <ul class="find" data-citedArticleID="1014336" data-doi="10.1517/14656566.7.5.631"><li><a href="http://dx.doi.org/10.1517/14656566.7.5.631" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Herceptin+Adjuvant+%28HERA%29+Trial+Study+Team+Trastuzumab+after+adjuvant+chemotherapy+in+HER2-positive+breast+cancer." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Herceptin+Adjuvant+%28HERA%29+Trial+Study+Team+Trastuzumab+after+adjuvant+chemotherapy+in+HER2-positive+breast+cancer.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">9.
              </span><a name="pone.0001138-Press1" id="pone.0001138-Press1"></a>Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, et al.  (2002) Evaluation of <em>HER2</em>/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J Clin Oncol  20: 3095–3105.  <ul class="find" data-citedArticleID="1014338"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Evaluation+of+HER2%2Fneu+gene+amplification+and+overexpression%3A+comparison+of+frequently+used+assay+methods+in+a+molecularly+characterized+cohort+of+breast+cancer+specimens&amp;auth=&amp;atitle=Evaluation+of+HER2%2Fneu+gene+amplification+and+overexpression%3A+comparison+of+frequently+used+assay+methods+in+a+molecularly+characterized+cohort+of+breast+cancer+specimens" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Evaluation+of+HER2%2Fneu+gene+amplification+and+overexpression%3A+comparison+of+frequently+used+assay+methods+in+a+molecularly+characterized+cohort+of+breast+cancer+specimens" target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Evaluation+of+HER2%2Fneu+gene+amplification+and+overexpression%3A+comparison+of+frequently+used+assay+methods+in+a+molecularly+characterized+cohort+of+breast+cancer+specimens%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">10.
              </span><a name="pone.0001138-VincentSalomon1" id="pone.0001138-VincentSalomon1"></a>Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Denoux Y, et al.  (2003) Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology  42: 337–347.  <ul class="find" data-citedArticleID="1014358" data-doi="10.1046/j.1365-2559.2003.01598.x"><li><a href="http://dx.doi.org/10.1046/j.1365-2559.2003.01598.x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Calibration+of+immunohistochemistry+for+assessment+of+HER2+in+breast+cancer%3A+results+of+the+French+multicentre+GEFPICS+study." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Calibration+of+immunohistochemistry+for+assessment+of+HER2+in+breast+cancer%3A+results+of+the+French+multicentre+GEFPICS+study.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">11.
              </span><a name="pone.0001138-Ellis1" id="pone.0001138-Ellis1"></a>Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, et al.  (2004) Best Practice No 176: Updated recommendations for <em>HER2</em> testing in the UK. J Clin Pathol  57: 233–237.  <ul class="find" data-citedArticleID="1014298" data-doi="10.1136/jcp.2003.007724"><li><a href="http://dx.doi.org/10.1136/jcp.2003.007724" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Best+Practice+No+176%3A+Updated+recommendations+for+HER2+testing+in+the+UK." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Best+Practice+No+176%3A+Updated+recommendations+for+HER2+testing+in+the+UK.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">12.
              </span><a name="pone.0001138-Tubbs1" id="pone.0001138-Tubbs1"></a>Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, et al.  (2001) Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol  19: 2714–2721.  <ul class="find" data-citedArticleID="1014354"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Discrepancies+in+clinical+laboratory+testing+of+eligibility+for+trastuzumab+therapy%3A+apparent+immunohistochemical+false-positives+do+not+get+the+message.&amp;auth=&amp;atitle=Discrepancies+in+clinical+laboratory+testing+of+eligibility+for+trastuzumab+therapy%3A+apparent+immunohistochemical+false-positives+do+not+get+the+message." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Discrepancies+in+clinical+laboratory+testing+of+eligibility+for+trastuzumab+therapy%3A+apparent+immunohistochemical+false-positives+do+not+get+the+message." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Discrepancies+in+clinical+laboratory+testing+of+eligibility+for+trastuzumab+therapy%3A+apparent+immunohistochemical+false-positives+do+not+get+the+message.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">13.
              </span><a name="pone.0001138-Perez1" id="pone.0001138-Perez1"></a>Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, et al.  (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol  24: 3032–3038.  <ul class="find" data-citedArticleID="1014334" data-doi="10.1200/jco.2005.03.4744"><li><a href="http://dx.doi.org/10.1200/jco.2005.03.4744" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=HER2+testing+by+local%2C+central%2C+and+reference+laboratories+in+specimens+from+the+North+Central+Cancer+Treatment+Group+N9831+intergroup+adjuvant+trial." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22HER2+testing+by+local%2C+central%2C+and+reference+laboratories+in+specimens+from+the+North+Central+Cancer+Treatment+Group+N9831+intergroup+adjuvant+trial.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">14.
              </span><a name="pone.0001138-Wolff1" id="pone.0001138-Wolff1"></a>Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al.  (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol  25: 118–145.  <ul class="find" data-citedArticleID="1014360" data-doi="10.1200/jco.2006.09.2775"><li><a href="http://dx.doi.org/10.1200/jco.2006.09.2775" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=American+Society+of+Clinical+Oncology%2FCollege+of+American+Pathologists+guideline+recommendations+for+human+epidermal+growth+factor+receptor+2+testing+in+breast+cancer." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22American+Society+of+Clinical+Oncology%2FCollege+of+American+Pathologists+guideline+recommendations+for+human+epidermal+growth+factor+receptor+2+testing+in+breast+cancer.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">15.
              </span><a name="pone.0001138-Singleton1" id="pone.0001138-Singleton1"></a>Singleton TP, Perrone T, Oakley G, Niehans GA, Carson L, et al.  (1994) Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage. Cancer  73: 1460–1466.  <ul class="find" data-citedArticleID="1014346" data-doi="10.1002/1097-0142(19940301)73:5<1460::aid-cncr2820730523&gt;3.0.co;2-z"><li><a href="http://dx.doi.org/10.1002/1097-0142(19940301)73:5<1460::aid-cncr2820730523&gt;3.0.co;2-z" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Activation+of+c-erbB-2+and+prognosis+in+ovarian+carcinoma.+Comparison+with+histologic+type%2C+grade%2C+and+stage." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Activation+of+c-erbB-2+and+prognosis+in+ovarian+carcinoma.+Comparison+with+histologic+type%2C+grade%2C+and+stage.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">16.
              </span><a name="pone.0001138-Meden1" id="pone.0001138-Meden1"></a>Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, et al.  (1994) Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol  13: 45–53.  <ul class="find" data-citedArticleID="1014328" data-doi="10.1097/00004347-199401000-00006"><li><a href="http://dx.doi.org/10.1097/00004347-199401000-00006" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Overexpression+of+the+oncogene+c-erb+B2+in+primary+ovarian+cancer%3A+evaluation+of+the+prognostic+value+in+a+Cox+proportional+hazards+multiple+regression." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Overexpression+of+the+oncogene+c-erb+B2+in+primary+ovarian+cancer%3A+evaluation+of+the+prognostic+value+in+a+Cox+proportional+hazards+multiple+regression.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">17.
              </span><a name="pone.0001138-Felip1" id="pone.0001138-Felip1"></a>Felip E, Del Campo JM, Rubio D, Vera R, del Campo JM, et al.  (1995) Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer  75: 2147–2152.  <ul class="find" data-citedArticleID="1014304" data-doi="10.1002/1097-0142(19950415)75:8<2147::aid-cncr2820750818&gt;3.0.co;2-8"><li><a href="http://dx.doi.org/10.1002/1097-0142(19950415)75:8<2147::aid-cncr2820750818&gt;3.0.co;2-8" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Overexpression+of+c-erbB-2+in+epithelial+ovarian+cancer.+Prognostic+value+and+relationship+with+response+to+chemotherapy." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Overexpression+of+c-erbB-2+in+epithelial+ovarian+cancer.+Prognostic+value+and+relationship+with+response+to+chemotherapy.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">18.
              </span><a name="pone.0001138-Fajac1" id="pone.0001138-Fajac1"></a>Fajac A, Benard J, Lhomme C, Rey A, Duvillard P, et al.  (1995) c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer  64: 146–151.  <ul class="find" data-citedArticleID="1014302" data-doi="10.1002/ijc.2910640213"><li><a href="http://dx.doi.org/10.1002/ijc.2910640213" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=c-erbB2+gene+amplification+and+protein+expression+in+ovarian+epithelial+tumors%3A+evaluation+of+their+respective+prognostic+significance+by+multivariate+analysis." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22c-erbB2+gene+amplification+and+protein+expression+in+ovarian+epithelial+tumors%3A+evaluation+of+their+respective+prognostic+significance+by+multivariate+analysis.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">19.
              </span><a name="pone.0001138-Young1" id="pone.0001138-Young1"></a>Young SR, Liu WH, Brock JA, Smith ST (1996) ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization. Genes Chromosomes Cancer  16: 130–137.  <ul class="find" data-citedArticleID="1014366" data-doi="10.1002/(sici)1098-2264(199606)16:2<130::aid-gcc7&gt;3.0.co;2-0"><li><a href="http://dx.doi.org/10.1002/(sici)1098-2264(199606)16:2<130::aid-gcc7&gt;3.0.co;2-0" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=ERBB2+and+chromosome+17+centromere+studies+of+ovarian+cancer+by+fluorescence+in+situ+hybridization." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22ERBB2+and+chromosome+17+centromere+studies+of+ovarian+cancer+by+fluorescence+in+situ+hybridization.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">20.
              </span><a name="pone.0001138-Goff1" id="pone.0001138-Goff1"></a>Goff BA, Ries JA, Els LP, Coltrera MD, Gown AM (1998) Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol  70: 378–385.  <ul class="find" data-citedArticleID="1014308" data-doi="10.1006/gyno.1998.5094"><li><a href="http://dx.doi.org/10.1006/gyno.1998.5094" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Immunophenotype+of+ovarian+cancer+as+predictor+of+clinical+outcome%3A+evaluation+at+primary+surgery+and+second-look+procedure." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Immunophenotype+of+ovarian+cancer+as+predictor+of+clinical+outcome%3A+evaluation+at+primary+surgery+and+second-look+procedure.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">21.
              </span><a name="pone.0001138-Ferrandina1" id="pone.0001138-Ferrandina1"></a>Ferrandina G, Ranelletti FO, Lauriola L, Fanfani F, Legge F, et al.  (2002) Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and <em>HER2</em>/neu expression in ovarian cancer. Gynecol Oncol  85: 305–310.  <ul class="find" data-citedArticleID="1014306" data-doi="10.1006/gyno.2002.6620"><li><a href="http://dx.doi.org/10.1006/gyno.2002.6620" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Cyclooxygenase-2+%28COX-2%29%2C+epidermal+growth+factor+receptor+%28EGFR%29%2C+and+HER2%2Fneu+expression+in+ovarian+cancer." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Cyclooxygenase-2+%28COX-2%29%2C+epidermal+growth+factor+receptor+%28EGFR%29%2C+and+HER2%2Fneu+expression+in+ovarian+cancer.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">22.
              </span><a name="pone.0001138-Bookman1" id="pone.0001138-Bookman1"></a>Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003) Evaluation of monoclonal humanized anti-<em>HER2</em> antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of <em>HER2</em>: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol  21: 283–290.  <ul class="find" data-citedArticleID="1014288" data-doi="10.1200/jco.2003.10.104"><li><a href="http://dx.doi.org/10.1200/jco.2003.10.104" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Evaluation+of+monoclonal+humanized+anti-HER2+antibody%2C+trastuzumab%2C+in+patients+with+recurrent+or+refractory+ovarian+or+primary+peritoneal+carcinoma+with+overexpression+of+HER2%3A+a+phase+II+trial+of+the+Gynecologic+Oncology+Group." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Evaluation+of+monoclonal+humanized+anti-HER2+antibody%2C+trastuzumab%2C+in+patients+with+recurrent+or+refractory+ovarian+or+primary+peritoneal+carcinoma+with+overexpression+of+HER2%3A+a+phase+II+trial+of+the+Gynecologic+Oncology+Group.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">23.
              </span><a name="pone.0001138-Hogdall1" id="pone.0001138-Hogdall1"></a>Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, et al.  (2003) Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer  98: 66–73.  <ul class="find" data-citedArticleID="1014312" data-doi="10.1002/cncr.11476"><li><a href="http://dx.doi.org/10.1002/cncr.11476" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Distribution+of+HER-2+overexpression+in+ovarian+carcinoma+tissue+and+its+prognostic+value+in+patients+with+ovarian+carcinoma%3A+from+the+Danish+MALOVA+Ovarian+Cancer+Study." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Distribution+of+HER-2+overexpression+in+ovarian+carcinoma+tissue+and+its+prognostic+value+in+patients+with+ovarian+carcinoma%3A+from+the+Danish+MALOVA+Ovarian+Cancer+Study.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">24.
              </span><a name="pone.0001138-CamilleriBrot1" id="pone.0001138-CamilleriBrot1"></a>Camilleri-Broët S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, et al.  (2004) HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol  15: 104–112.  <ul class="find" data-citedArticleID="1014290" data-doi="10.1093/annonc/mdh021"><li><a href="http://dx.doi.org/10.1093/annonc/mdh021" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=HER-2+overexpression+is+an+independent+marker+of+poor+prognosis+of+advanced+primary+ovarian+carcinoma%3A+a+multicenter+study+of+the+GINECO+group." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22HER-2+overexpression+is+an+independent+marker+of+poor+prognosis+of+advanced+primary+ovarian+carcinoma%3A+a+multicenter+study+of+the+GINECO+group.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">25.
              </span><a name="pone.0001138-Cloven1" id="pone.0001138-Cloven1"></a>Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP (2004) <em>In vitro</em> chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol  92: 160–166.  <ul class="find" data-citedArticleID="1014292" data-doi="10.1016/j.ygyno.2003.09.030"><li><a href="http://dx.doi.org/10.1016/j.ygyno.2003.09.030" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=In+vitro+chemoresistance+and+biomarker+profiles+are+unique+for+histologic+subtypes+of+epithelial+ovarian+cancer." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22In+vitro+chemoresistance+and+biomarker+profiles+are+unique+for+histologic+subtypes+of+epithelial+ovarian+cancer.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">26.
              </span><a name="pone.0001138-Erkinheimo1" id="pone.0001138-Erkinheimo1"></a>Erkinheimo TL, Lassus H, Finne P, van Rees BP, Leminen A, et al.  (2004) Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res  10: 538–545.  <ul class="find" data-citedArticleID="1014300" data-doi="10.1158/1078-0432.ccr-0132-03"><li><a href="http://dx.doi.org/10.1158/1078-0432.ccr-0132-03" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Elevated+cyclooxygenase-2+expression+is+associated+with+altered+expression+of+p53+and+SMAD4%2C+amplification+of+HER-2%2Fneu%2C+and+poor+outcome+in+serous+ovarian+carcinoma." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Elevated+cyclooxygenase-2+expression+is+associated+with+altered+expression+of+p53+and+SMAD4%2C+amplification+of+HER-2%2Fneu%2C+and+poor+outcome+in+serous+ovarian+carcinoma.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">27.
              </span><a name="pone.0001138-Kupryjanczyk1" id="pone.0001138-Kupryjanczyk1"></a>Kupryjanczyk J, Madry R, Plisiecka-Halasa J, Bar J, Kraszewska E, et al.  (2004) TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. Br J Cancer  91: 1916–1923.  <ul class="find" data-citedArticleID="1014314"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=TP53+status+determines+clinical+significance+of+ERBB2+expression+in+ovarian+cancer.&amp;auth=&amp;atitle=TP53+status+determines+clinical+significance+of+ERBB2+expression+in+ovarian+cancer." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=TP53+status+determines+clinical+significance+of+ERBB2+expression+in+ovarian+cancer." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22TP53+status+determines+clinical+significance+of+ERBB2+expression+in+ovarian+cancer.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">28.
              </span><a name="pone.0001138-Lassus1" id="pone.0001138-Lassus1"></a>Lassus H, Leminen A, Vayrynen A, et al.  (2004) ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol  92: 31–39.  <ul class="find" data-citedArticleID="1014316" data-doi="10.1016/j.ygyno.2003.10.010"><li><a href="http://dx.doi.org/10.1016/j.ygyno.2003.10.010" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=ERBB2+amplification+is+superior+to+protein+expression+status+in+predicting+patient+outcome+in+serous+ovarian+carcinoma." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22ERBB2+amplification+is+superior+to+protein+expression+status+in+predicting+patient+outcome+in+serous+ovarian+carcinoma.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">29.
              </span><a name="pone.0001138-Mano1" id="pone.0001138-Mano1"></a>Mano MS, Awada A, Di Leo A, Durbecq V, Paesmans M, et al.  (2004) Rates of topoisomerase II-alpha and <em>HER2</em> gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol  92: 887–895.  <ul class="find" data-citedArticleID="1014320" data-doi="10.1016/j.ygyno.2003.12.010"><li><a href="http://dx.doi.org/10.1016/j.ygyno.2003.12.010" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Rates+of+topoisomerase+II-alpha+and+HER2+gene+amplification+and+expression+in+epithelial+ovarian+carcinoma." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Rates+of+topoisomerase+II-alpha+and+HER2+gene+amplification+and+expression+in+epithelial+ovarian+carcinoma.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">30.
              </span><a name="pone.0001138-Nielsen1" id="pone.0001138-Nielsen1"></a>Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A (2004) Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer  14: 1086–1096.  <ul class="find" data-citedArticleID="1014330" data-doi="10.1111/j.1048-891x.2004.14606.x"><li><a href="http://dx.doi.org/10.1111/j.1048-891x.2004.14606.x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Prognostic+significance+of+p53%2C+Her-2%2C+and+EGFR+overexpression+in+borderline+and+epithelial+ovarian+cancer." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Prognostic+significance+of+p53%2C+Her-2%2C+and+EGFR+overexpression+in+borderline+and+epithelial+ovarian+cancer.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">31.
              </span><a name="pone.0001138-Lee1" id="pone.0001138-Lee1"></a>Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, et al.  (2005) Assessment of Her-1, Her-<em>2</em>, and Her-3 expression and Her-<em>2</em> amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol  24: 147–152.  <ul class="find" data-citedArticleID="1014318" data-doi="10.1097/01.pgp.0000152026.39268.57"><li><a href="http://dx.doi.org/10.1097/01.pgp.0000152026.39268.57" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Assessment+of+Her-1%2C+Her-2%2C+and+Her-3+expression+and+Her-2+amplification+in+advanced+stage+ovarian+carcinoma." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Assessment+of+Her-1%2C+Her-2%2C+and+Her-3+expression+and+Her-2+amplification+in+advanced+stage+ovarian+carcinoma.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">32.
              </span><a name="pone.0001138-Verri1" id="pone.0001138-Verri1"></a>Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, et al.  (2005) <em>HER2</em>/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Oncology  68: 154–161.  <ul class="find" data-citedArticleID="1014356" data-doi="10.1159/000086958"><li><a href="http://dx.doi.org/10.1159/000086958" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=HER2%2Fneu+oncoprotein+overexpression+in+epithelial+ovarian+cancer%3A+evaluation+of+its+prevalence+and+prognostic+significance." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22HER2%2Fneu+oncoprotein+overexpression+in+epithelial+ovarian+cancer%3A+evaluation+of+its+prevalence+and+prognostic+significance.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">33.
              </span><a name="pone.0001138-Mayr1" id="pone.0001138-Mayr1"></a>Mayr D, Kanitz V, Amann G, Engel J, Burges A, et al.  (2006) HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology  48: 149–156.  <ul class="find" data-citedArticleID="1014326" data-doi="10.1111/j.1365-2559.2005.02306.x"><li><a href="http://dx.doi.org/10.1111/j.1365-2559.2005.02306.x" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=HER-2%2Fneu+gene+amplification+in+ovarian+tumours%3A+a+comprehensive+immunohistochemical+and+FISH+analysis+on+tissue+microarrays." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22HER-2%2Fneu+gene+amplification+in+ovarian+tumours%3A+a+comprehensive+immunohistochemical+and+FISH+analysis+on+tissue+microarrays.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">34.
              </span><a name="pone.0001138-Press2" id="pone.0001138-Press2"></a>Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, et al.  (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res  11: 6598–6607.  <ul class="find" data-citedArticleID="1014340" data-doi="10.1158/1078-0432.ccr-05-0636"><li><a href="http://dx.doi.org/10.1158/1078-0432.ccr-05-0636" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Diagnostic+evaluation+of+HER-2+as+a+molecular+target%3A+an+assessment+of+accuracy+and+reproducibility+of+laboratory+testing+in+large%2C+prospective%2C+randomized+clinical+trials." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Diagnostic+evaluation+of+HER-2+as+a+molecular+target%3A+an+assessment+of+accuracy+and+reproducibility+of+laboratory+testing+in+large%2C+prospective%2C+randomized+clinical+trials.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">35.
              </span><a name="pone.0001138-Gouvea1" id="pone.0001138-Gouvea1"></a>Gouvea AP, Milanezi F, Olson SJ, Leitao D, Schmitt FC, et al.  (2006) Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol.  14: 103–8.  <ul class="find" data-citedArticleID="1014310" data-doi="10.1097/01.pai.0000155794.64525.11"><li><a href="http://dx.doi.org/10.1097/01.pai.0000155794.64525.11" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Selecting+antibodies+to+detect+HER2+overexpression+by+immunohistochemistry+in+invasive+mammary+carcinomas." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Selecting+antibodies+to+detect+HER2+overexpression+by+immunohistochemistry+in+invasive+mammary+carcinomas.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">36.
              </span><a name="pone.0001138-Couturier1" id="pone.0001138-Couturier1"></a>Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, et al.  (2000) Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol  13: 1238–43.  <ul class="find" data-citedArticleID="1014296" data-doi="10.1038/modpathol.3880228"><li><a href="http://dx.doi.org/10.1038/modpathol.3880228" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Strong+correlation+between+results+of+fluorescent+in+situ+hybridization+and+immunohistochemistry+for+the+assessment+of+the+ERBB2+%28HER-2%2Fneu%29+gene+status+in+breast+carcinoma." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Strong+correlation+between+results+of+fluorescent+in+situ+hybridization+and+immunohistochemistry+for+the+assessment+of+the+ERBB2+%28HER-2%2Fneu%29+gene+status+in+breast+carcinoma.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">37.
              </span><a name="pone.0001138-Tokunaga1" id="pone.0001138-Tokunaga1"></a>Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, et al.  (2006) Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol  11: 199–208.  <ul class="find" data-citedArticleID="1014352" data-doi="10.1007/s10147-006-0575-4"><li><a href="http://dx.doi.org/10.1007/s10147-006-0575-4" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Trastuzumab+and+breast+cancer%3A+developments+and+current+status." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Trastuzumab+and+breast+cancer%3A+developments+and+current+status.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">38.
              </span><a name="pone.0001138-Barrett1" id="pone.0001138-Barrett1"></a>Barrett C, Magee H, O'Toole D, Daly S, Jeffers M, et al.  (2007) Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry? J Clin Pathol  60: 690–693.  <ul class="find" data-citedArticleID="1014284" data-doi="10.1136/jcp.2006.039602"><li><a href="http://dx.doi.org/10.1136/jcp.2006.039602" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Amplification+of+the+HER2+gene+in+breast+cancers+testing+2%2B+weak+positive+by+HercepTest+immunohistochemistry%3A+false-positive+or+false-negative+immunohistochemistry%3F" target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Amplification+of+the+HER2+gene+in+breast+cancers+testing+2%2B+weak+positive+by+HercepTest+immunohistochemistry%3A+false-positive+or+false-negative+immunohistochemistry%3F%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">39.
              </span><a name="pone.0001138-SerranoOlvera1" id="pone.0001138-SerranoOlvera1"></a>Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, Candelaria M, De la Garza-Salazar J (2006) Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev  32: 180–190.  <ul class="find" data-citedArticleID="1014344" data-doi="10.1016/j.ctrv.2006.01.001"><li><a href="http://dx.doi.org/10.1016/j.ctrv.2006.01.001" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Prognostic%2C+predictive+and+therapeutic+implications+of+HER2+in+invasive+epithelial+ovarian+cancer." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Prognostic%2C+predictive+and+therapeutic+implications+of+HER2+in+invasive+epithelial+ovarian+cancer.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">40.
              </span><a name="pone.0001138-Berchuck1" id="pone.0001138-Berchuck1"></a>Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, et al.  (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res  50: 4087–4091.  <ul class="find" data-citedArticleID="1014286"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Overexpression+of+HER-2%2Fneu+is+associated+with+poor+survival+in+advanced+epithelial+ovarian+cancer.&amp;auth=&amp;atitle=Overexpression+of+HER-2%2Fneu+is+associated+with+poor+survival+in+advanced+epithelial+ovarian+cancer." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Overexpression+of+HER-2%2Fneu+is+associated+with+poor+survival+in+advanced+epithelial+ovarian+cancer." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Overexpression+of+HER-2%2Fneu+is+associated+with+poor+survival+in+advanced+epithelial+ovarian+cancer.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">41.
              </span><a name="pone.0001138-Yamauchi1" id="pone.0001138-Yamauchi1"></a>Yamauchi H, Stearns V, Hayes DF (2001) When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol  19: 2334–2356.  <ul class="find" data-citedArticleID="1014362"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=When+is+a+tumor+marker+ready+for+prime+time%3F+A+case+study+of+c-erbB-2+as+a+predictive+factor+in+breast+cancer.&amp;auth=&amp;atitle=When+is+a+tumor+marker+ready+for+prime+time%3F+A+case+study+of+c-erbB-2+as+a+predictive+factor+in+breast+cancer." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=When+is+a+tumor+marker+ready+for+prime+time%3F+A+case+study+of+c-erbB-2+as+a+predictive+factor+in+breast+cancer." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22When+is+a+tumor+marker+ready+for+prime+time%3F+A+case+study+of+c-erbB-2+as+a+predictive+factor+in+breast+cancer.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">42.
              </span><a name="pone.0001138-Martin1" id="pone.0001138-Martin1"></a>Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, et al.  (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med  352: 2302–2313.  <ul class="find" data-citedArticleID="1014322" data-doi="10.1056/nejmoa043681"><li><a href="http://dx.doi.org/10.1056/nejmoa043681" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Adjuvant+docetaxel+for+node-positive+breast+cancer." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Adjuvant+docetaxel+for+node-positive+breast+cancer.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">43.
              </span><a name="pone.0001138-Aigner1" id="pone.0001138-Aigner1"></a>Aigner A, Hsieh SS, Malerczyk C, Czubayko F (2000) Reversal of <em>HER2</em> over-expression renders human ovarian cancer cells highly resistant to taxol. Toxicology  144: 221–228.  <ul class="find" data-citedArticleID="1014282" data-doi="10.1016/s0300-483x(99)00210-3"><li><a href="http://dx.doi.org/10.1016/s0300-483x(99)00210-3" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Reversal+of+HER2+over-expression+renders+human+ovarian+cancer+cells+highly+resistant+to+taxol." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Reversal+of+HER2+over-expression+renders+human+ovarian+cancer+cells+highly+resistant+to+taxol.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li></ol></div>

  </div>

      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.XML" value="94917"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.PDF" value="292635"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t001.PNG_L" value="127305"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t001.PNG_M" value="82878"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t001.PNG_S" value="15079"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t001.TIF" value="751962"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t001.PNG_I" value="69002"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g001.PNG_L" value="1596959"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g001.PNG_M" value="588287"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g001.PNG_S" value="20667"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g001.TIF" value="2034272"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g001.PNG_I" value="228161"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g002.PNG_L" value="246404"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g002.PNG_M" value="75854"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g002.PNG_S" value="11459"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g002.TIF" value="589076"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g002.PNG_I" value="44626"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g003.PNG_L" value="507343"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g003.PNG_M" value="55735"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g003.PNG_S" value="6183"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g003.TIF" value="1167672"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g003.PNG_I" value="20365"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t002.PNG_L" value="132882"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t002.PNG_M" value="72796"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t002.PNG_S" value="11135"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t002.TIF" value="698624"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t002.PNG_I" value="22350"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t003.PNG_L" value="108936"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t003.PNG_M" value="59796"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t003.PNG_S" value="10146"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t003.TIF" value="565270"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.t003.PNG_I" value="18222"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g004.PNG_L" value="593018"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g004.PNG_M" value="26896"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g004.PNG_S" value="5630"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g004.TIF" value="1007674"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001138.g004.PNG_I" value="9489"/>

</div>
<div class="sidebar">

  <div class="article-actions cf">
      <div class="download">
        <span class="btn"><a href="/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0001138&amp;representation=PDF" title="Download" target="_blank">Download PDF</a></span>
      </div>
      <div class="btn-reveal dropdown">
        <div class="dropdown-icon">
          <span class="btn">&nbsp;</span>
        </div>

        <div class="content">
          <ul class="bullet">
            <li><a href="/article/citationList.action?articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0001138" title="Download citations">Citation</a></li>
            <li><a href="/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0001138&amp;representation=XML" title="Download article XML">XML</a></li>
          </ul>
        </div>
      </div> <!-- end btn-reveal dropdown-->


    <div class="btn-reveal flt-l">
        <span class="btn">Print</span>
        <div class="content">
            <ul class="bullet">
                <li id="print-article"><a href="#" onclick="if(typeof(_gaq) != 'undefined'){ _gaq.push(['_trackEvent','Article', 'Print', 'Click']); } window.print(); return false;" title="Print Article">Print article</a></li>
                <li>
                  <a href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=7&doi=10.1371/journal.pone.0001138&volume=&issue=&title=HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients&author_name=Marianne%20Tuefferd%2C%20J%C3%A9r%C3%B4me%20Couturier%2C%20Fr%C3%A9d%C3%A9rique%20Penault-Llorca%2C%20Anne%20Vincent-Salomon%2C%20Philippe%20Bro%C3%ABt%2C%20Jean-Paul%20Guastalla%2C%20Djelila%20Allouache%2C%20Martin%20Combe%2C%20B%C3%A9atrice%20Weber%2C%20Eric%20Pujade-Lauraine%2C%20Sophie%20Camilleri-Bro%C3%ABt&start_page=1&end_page=8" title="Odyssey Press">EzReprint</a>
                </li>
            </ul>
        </div>
    </div>

    <div class="btn-reveal flt-r">
        <span class="btn">Share</span>
        <div class="content">
            <ul class="social">
                <li><a href="http://www.reddit.com/submit?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001138" target="_blank" title="Submit to Reddit"><img src="/images/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

                <li><a href="https://plus.google.com/share?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001138" target="_blank" title="Share on Google+"><img src="/images/icon.gplus.16.png" width="16" height="16" alt="Google+">Google+</a></li>

                <li><a href="http://www.stumbleupon.com/submit?url=http%3A%2F%2Fwww.plosone.org%2Farticle%2Finfo%253Adoi%252F10.1371%252Fjournal.pone.0001138" target="_blank" title="Add to StumbleUpon"><img src="/images/icon.stumble.16.png" width="16" height="16" alt="StumbleUpon">StumbleUpon</a></li>

                <li><a href="http://www.facebook.com/share.php?u=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001138&amp;t=HER2%20Status%20in%20Ovarian%20Carcinomas%3A%20A%20Multicenter%20GINECO%20Study%20of%20320%20Patients" target="_blank" title="Share on Facebook"><img src="/images/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>

                <li><a href="http://www.linkedin.com/shareArticle?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001138&title=HER2%20Status%20in%20Ovarian%20Carcinomas%3A%20A%20Multicenter%20GINECO%20Study%20of%20320%20Patients&summary=Checkout%20this%20article%20I%20found%20at%20PLOS" target="_blank" title="Add to LinkedIn"><img src="/images/icon.linkedin.16.png" width="16" height="16" alt="Mendeley">LinkedIn</a></li>

                <li><a href="http://www.citeulike.org/posturl?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001138&amp;title=HER2%20Status%20in%20Ovarian%20Carcinomas%3A%20A%20Multicenter%20GINECO%20Study%20of%20320%20Patients" target="_blank" title="Add to CiteULike"><img src="/images/icon.cul.16.png" width="16" height="16" alt="CiteULike">CiteULike</a></li>

                <li><a href="http://www.mendeley.com/import/?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001138" target="_blank" title="Add to Mendeley"><img src="/images/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

                <li><a href="https://www.pubchase.com/library?add_aid=10.1371%2Fjournal.pone.0001138&amp;source=plos" target="_blank" title="Add to PubChase"><img src="/images/icon.pc.16.png" width="16" height="16" alt="PubChase">PubChase</a></li>


                <script type="text/javascript">
                    // replace tweet with one that's pre-shortened to 140 chars
                    function truncateTweetText() {
                        var twtTitle = 'HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients';
                        var twtUrl = 'http://dx.plos.org/10.1371/journal.pone.0001138';
                        // all URLs posted to twitter get auto-shortened to 20 chars.
                        var maxLength = 140 - (20 + 1);
                        // truncate the title to include space for twtTag and ellipsis (here, 10 = tag length + space + ellipsis)
                        if (twtTitle.length > maxLength) { twtTitle = twtTitle.substr(0, (maxLength - 10)) + '...'; }
                        // set the href to use the shortened tweet
                        $('#twitter-share-link').prop('href', 'http://twitter.com/intent/tweet?text=' + encodeURIComponent('#PLOSONE: ' + twtTitle + ' ' + twtUrl));
                    }
                </script>
                <li><a href="http://twitter.com/intent/tweet?text=#PLOSONE%3A%20HER2%20Status%20in%20Ovarian%20Carcinomas%3A%20A%20Multicenter%20GINECO%20Study%20of%20320%20Patients http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001138" onclick="truncateTweetText();" target="_blank" title="Share on Twitter" id="twitter-share-link"><img src="/images/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li>

                <li><a href="/article/email/info%3Adoi%2F10.1371%2Fjournal.pone.0001138" title="Email this article"><img src="/images/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>
            </ul>
        </div>
    </div><!--end btn-reveal flt-r-->
</div><!-- end article-actions-->

<!-- begin Crossmark -->

<a id="open-crossmark" href="#" style="margin-top: -28px; display:block"><img style="border: 0; display: none;
 padding: 10px 0 18px 0;"  id="crossmark-icon" src="/images/logo-crossmark-bw.png" /></a>
<div id="crossmark-dialog" style="display: none;" title="">
    <!-- the external CrossMark data is loaded inside this iframe -->
    <iframe id="crossmark-dialog-frame" frameborder="0"></iframe>
</div>

<!-- end crossmark -->


<div class="block" id="subject-area-sidebar-block">
    <div class="header">
        <h3>Subject Areas</h3><div title="More information" id="subject-area-sidebar-block-help-icon"><img align="right"
                                                                                                           alt="info" src="/images/button_info.png"/><div id="subject-area-sidebar-block-help"><img align="right"
                                                                                                                                                                                                    src="/images/button_info.png"/><p>
        <b>We want your feedback.</b> Do these subject areas make sense for this article? If not, click the flag
        next to the incorrect subject area and we will review it. Thanks for your help!
    </p></div></div>
    </div>


    <ul id="subject-area-sidebar-list">











          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Breast+cancer%22" title="Search for articles in the subject area:'Breast cancer'"><div class="flagText">Breast cancer</div></a>
              <div data-categoryid="18763" data-articleid="25110"
                   data-categoryname="Breast cancer"
                   class="flagImage" title="Flag 'Breast cancer' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Chemotherapy%22" title="Search for articles in the subject area:'Chemotherapy'"><div class="flagText">Chemotherapy</div></a>
              <div data-categoryid="22865" data-articleid="25110"
                   data-categoryname="Chemotherapy"
                   class="flagImage" title="Flag 'Chemotherapy' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Cytoplasmic+staining%22" title="Search for articles in the subject area:'Cytoplasmic staining'"><div class="flagText">Cytoplasmic staining</div></a>
              <div data-categoryid="17577" data-articleid="25110"
                   data-categoryname="Cytoplasmic staining"
                   class="flagImage" title="Flag 'Cytoplasmic staining' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Fluorescent+in+situ+hybridization%22" title="Search for articles in the subject area:'Fluorescent in situ hybridization'"><div class="flagText">Fluorescent in situ hybridization</div></a>
              <div data-categoryid="32333" data-articleid="25110"
                   data-categoryname="Fluorescent in situ hybridization"
                   class="flagImage" title="Flag 'Fluorescent in situ hybridization' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Gene+amplification%22" title="Search for articles in the subject area:'Gene amplification'"><div class="flagText">Gene amplification</div></a>
              <div data-categoryid="19947" data-articleid="25110"
                   data-categoryname="Gene amplification"
                   class="flagImage" title="Flag 'Gene amplification' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Immunohistochemistry+techniques%22" title="Search for articles in the subject area:'Immunohistochemistry techniques'"><div class="flagText">Immunohistochemistry techniques</div></a>
              <div data-categoryid="19603" data-articleid="25110"
                   data-categoryname="Immunohistochemistry techniques"
                   class="flagImage" title="Flag 'Immunohistochemistry techniques' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Membrane+staining%22" title="Search for articles in the subject area:'Membrane staining'"><div class="flagText">Membrane staining</div></a>
              <div data-categoryid="17575" data-articleid="25110"
                   data-categoryname="Membrane staining"
                   class="flagImage" title="Flag 'Membrane staining' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Ovarian+cancer%22" title="Search for articles in the subject area:'Ovarian cancer'"><div class="flagText">Ovarian cancer</div></a>
              <div data-categoryid="23533" data-articleid="25110"
                   data-categoryname="Ovarian cancer"
                   class="flagImage" title="Flag 'Ovarian cancer' as inappropriate"></div>
          </li>
    </ul>
</div>

<div class="ad">
    <div class="title">Advertisement</div>






  <iframe id='a0852f54' name='a0852f54'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=381&amp;cb=4141'
    frameborder='0' scrolling='no' width='160' height='600'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a0852f54&amp;cb=7753'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=381&amp;cb=1771&amp;n=a0852f54'
      border='0' alt=''/>
    </a>
  </iframe>



</div>

<div id="twitter-alm-timeline" class="twitter-alm-timeline"></div>

<div class="block sidebar-comments">
    <div class="header">
        <h3>Comments</h3>
    </div>
      <p><a href="/annotation/listThread.action?root=17301">Referee Comments: Referee 1</a><br>Posted by PLoS_ONE_Group</p>
</div>

</div><!-- sidebar -->
    </div>
  </div>
</div>
<script src="http://wl.figshare.com/static/p_widget.js" type="text/javascript"></script><div id="pageftr">
  <div class="ftr-cols cf">
    <div class="col col-1">
      <img src="/images/logo-plos-footer.png" alt="PLOS Logo" class="logo" />
      <p><a href="/static/releaseNotes">Ambra 2.9.16</a> Managed Colocation provided <br />by <a href="http://www.isc.org/">Internet Systems Consortium</a>.<p>
      <div class="nav nav-aux">
        <a href="/static/privacy">Privacy Policy</a> |
        <a href="/static/terms">Terms of Use</a> |
        <a href="http://www.plos.org/advertise/">Advertise</a> |
        <a href="http://www.plos.org/about/media-inquiries/">Media Inquiries</a>
      </div>
    </div>
    <div class="col col-2">
      <p><a href="http://www.plos.org/publications/journals/">Publications</a></p>
      <div class="nav">
        <ul>
          <li><a href="http://www.plosbiology.org">PLOS Biology</a></li>
          <li><a href="http://www.plosmedicine.org">PLOS Medicine</a></li>
          <li><a href="http://www.ploscompbiol.org">PLOS Computational Biology</a></li>
          <li><a href="http://currents.plos.org">PLOS Currents</a></li>
          <li><a href="http://www.plosgenetics.org">PLOS Genetics</a></li>
          <li><a href="http://www.plospathogens.org">PLOS Pathogens</a></li>
          <li><a href="http://www.plosone.org">PLOS ONE</a></li>
          <li><a href="http://www.plosntds.org">PLOS Neglected Tropical Diseases</a></li>
        </ul>
      </div>
    </div>
    <div class="col col-3">
      <div class="nav">
        <p><a href="http://www.plos.org">plos.org</a></p>
        <p><a href="http://blogs.plos.org">Blogs</a></p>
        <p><a href="http://www.ploscollections.org">Collections</a></p>
        <p><a href="/feedback/new">Send us feedback</a></p>

        <p>California (US) corporation #C2354500, based in San Francisco</p>
      </div>
    </div>
  </div>
</div><!-- pageftr -->

</div><!-- end page-wrap, this div is in header.ftl -->
<script type="text/javascript" src="/javascript/jquery-1.8.1-min.js?v=Tm7VCOzZz3lE03ghpkS6SWkHbyI"></script>
<script type="text/javascript" src="/javascript/ga-min.js?v=lNQ4gt8QcPDatjsdOFl_FGpPhLY"></script>
<script type="text/javascript" src="/javascript/jquery.hoverIntent-min.js?v=mRiGNYY9cIXxVb8u0K_MdW7hHnc"></script>
<script type="text/javascript" src="/javascript/jquery.placeholder-min.js?v=21Pn56Ur9h1N4K4VZDa0nqI3Pxo"></script>
<script type="text/javascript" src="/javascript/jquery.jsonp-2.4.0-min.js?v=lqTpzoHfSq3I5Ygo01qq5WankEo"></script>
<script type="text/javascript" src="/javascript/jquery-ui-1.9.2.custom-min.js?v=raSSlfNO0YsV5uUpAKmTB9n5VTc"></script>
<script type="text/javascript" src="/javascript/jquery.tooltip-min.js?v=cw+6Smh+mdryIA25xvqIvHMrnZM"></script>
<script type="text/javascript" src="/javascript/jquery.uniform-min.js?v=kYUAnX6W2W_2fK3RIuQ2m_YFG9U"></script>
<script type="text/javascript" src="/javascript/jquery.pjax-min.js?v=939kLBjL5_YKbx71T1RHjYaD4l8"></script>
<script type="text/javascript" src="/javascript/imagesloaded-min.js?v=XeuAp8Gc3mvQUo+wZCSF8ttPwvw"></script>
<script type="text/javascript" src="/javascript/figviewer-min.js?v=yPUa0sUQ_iHkI+IRv2i9bjyZJFo"></script>
<script type="text/javascript" src="/javascript/global-min.js?v=0Q3PwjeaWtXYDnqIsQvnL_ou0qs"></script>
<script type="text/javascript" src="/javascript/jquery.touchswipe-min.js?v=huaek_e6HqTduvCNAN91dJolTyw"></script>
<script type="text/javascript" src="/javascript/jquery.base64-min.js?v=VwV1zeVqKZj5FCAdlK0q5NRxbBg"></script>
<script type="text/javascript" src="/javascript/alm-min.js?v=Y5gm6B0b4Kx2YHNObNrgEeBgXlY"></script>
<script type="text/javascript" src="/javascript/taxonomy-browser-min.js?v=vBVMuDMYkGJCXIUxLe35GoyiJNw"></script>
<script type="text/javascript" src="/javascript/jquery.filterize-min.js?v=j0ZKVnHyk2nhFy8eIuNJkp7xaM0"></script>
<script type="text/javascript" src="/javascript/plosone-min.js?v=TK4H4arL_XBSwwJq+K1N3kqYfAI"></script>
<script type="text/javascript" src="/javascript/twitter-min.js?v=xKgcxLsQFXy+at1ao1NVke8nFlM"></script>
<script type="text/javascript" src="/javascript/crossmark.1.4-min.js?v=3FO4k0SjwTaGNnKGNSqthar1080"></script>
<script type="text/javascript">
  var _sf_async_config={uid:16579,domain:"plosone.org"};
  (function(){
    function loadChartbeat() {
      window._sf_endpt=(new Date()).getTime();
      var e = document.createElement('script');
      e.setAttribute('language', 'javascript');
      e.setAttribute('type', 'text/javascript');
      e.setAttribute('src',
          (("https:" == document.location.protocol) ? "https://a248.e.akamai.net/chartbeat.download.akamai.com/102508/" : "http://static.chartbeat.com/") +
              "js/chartbeat.js");
      document.body.appendChild(e);
    }
    var oldonload = window.onload;
    window.onload = (typeof window.onload != 'function') ?
        loadChartbeat : function() { oldonload(); loadChartbeat(); };
  })();
</script>
<!-- <script type="application/javascript" src="http://crossmark.crossref.org/javascripts/v1.3/crossmark.min.js"></script> -->

</body>
</html>
